Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
1 
  
Protocol #:  LCI-HEM -MYE -CRD -004 (MMRC -073 CARJAK)  
TITLE: Phase I/II Study of Carfilzomib, Ruxolitinib and L ow-Dose 
Dexamethasone for Carfilzomib-Refractory Multiple Myeloma  
LAY TITLE: Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose 
Dexamethasone for Carfilzomib-Refractory Multiple Myeloma  
Coordinating Center:  
Levine Cancer Institute   
Research and Academic Headquarters  
1021 Morehead Medical Drive  
Charlotte, NC 28204 
 
Sponsor -Investigat or: 
Shebli Atrash , MD , MS   
Levine Cancer Institute  
Research and Academic Headquarters  
1021 Morehead Medical Drive  
Charlotte, NC 28204 
Telephone: (980)  442-4363 
Email: shebli.atrash @atrium health.org 
 
Statistician: 
James Symanowski, PhD  
Department of Biostatistics  
Levine Cancer Institute  
1021 Morehead Medical Drive  
Charlotte, NC 28204  
Telephone: (980) 442 -2348 
Email: james.symanowski@ atriumhealth.org  
Investigational New Drug (IND) # 141696  
 
______________________________________________________________________________ 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
2 
 The study will be conducted in compliance with the protocol, ICH -GCP and any applicable 
regulatory requirements.  
 
Confidential  
The information provided in this document is strictly confidential and is intended solely for the 
guidance of the clinical investigation.  Reproduction or disclosure of this document -  whether in 
part or in full  - to parties not associated with the clinica l investigation, or its use for any other 
purpose, without the prior written consent of the Sponsor -Investigator is not permitted.  
 
Throughout this document, symbols indicating proprietary names ( , TM) are not displayed.  
Hence, the appearance of product  names without these symbols does not imply that these names 
are not protected.  
    
 
   
 
   
 
    
 
 
 
 
 
   
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
3 
 Original Phase I/II / Version 6 / September 27, 20 22 
PROTOCOL SUMMARY 
Study Title  Pilot Phase I/II Study of Carfilzomib, Ruxolitinib  and low -dose Dexamethasone 
for Carfilzomib -Refractory Multiple Myeloma  
Indication  Multiple Myeloma  (MM)  
Clinical Phase  I/II 
 
Summary of  
Rationale  
 
 Despite major advances in therapy, MM is still considered an incurable 
malignancy.  While the introduction of immunomodulatory agents (IMiDs) and 
proteasome inhibitors (PIs), and advances in high dose therapy (HDT) 
administration have made an impact on progression free survival (PFS) and 
overall survival (OS) for MM patients in general, the majorit y of patients suffer 
relapses with progressively shorter disease -free intervals with each relapse. 
Therefore, it is imperative to identify the patients at high -risk of disease relapse 
and develop novel therapeutic regimens that extend PFS and OS in this gr oup 
of MM patients.  
Study Objectives  The primary objective of Phase I  is to establish the maximum tolerated dose 
(MTD) of ruxolitinib in combination with carfilzomib and dexamethasone . The 
primary objective of Phase II  is to evaluate PFS at 4 months in multiple 
myeloma subjects  who receive the combination treatment carfilzomib, 
dexamethasone and ruxolitinib. Secondary objectives include evaluation of 
objective response rate, clinical benefit rate, disease control rate, time to best 
response, PFS, overall survival, time to progression, duration of response 
(DOR ), any occurrence of adverse events or serious adverse events while on 
study. Exploratory objectives include exploring the correlation of pe ripheral 
blood mononucle ar cell ( PBMC ) SNPs and JAK inhibition with toxicities and 
treatment response, exploring the correlation of PBMC proteasome inhibition 
with toxicities and treatment response, and examining changes in biology of 
BM and BM plasma cells before and after treat ment with global gene 
expression profiling/RNA seq/whole genome sequence/proteomics.  
Sample  Up to 18 subjects  in Phase I and an additional 30 subjects  in Phase II 
 
 
Inclusion/ 
Exclusion   
 
 
 (See protocol for complete inclusion/exclusion criteria)  
Inclusion criteria:  
• Age > 18 years  
• Documented history of relapsed and or refractory multiple myeloma 
with > 2 lines of therapy and evidence of relapse or progression within 
60 days of  a carfilzomib containing regimen at dose ≥  27 mg/m2 
• Measurable disease  
• Evidence of adequate bone marrow rese rves  
• Evidence of adequate hepatic, renal, and cardiac function  
Exclusion Criteria:  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
4 
 • Non-secretory multiple myeloma  
• Known amyloidosis  
• Known POEMS syndrome  
• Clinically significant illne ss that, in the opinion of the  Investigator, 
places the subject at unacceptable risk for adverse outcome if he/she 
were to participate in the study  
• Pregnant or breastfeeding  
• Known human immunodeficiency virus (HIV) infection 
• Active hepatitis B and/or hepatitis C infection  
• “Currently act ive” second malignancy, other than non- melanoma skin 
cancer and carcinoma in situ of the cervix  
 
Dosage/ Dosage  
Form, Route,  
And Dose  
Regimen  Phase I : Carfilzomib will be administered at 56 mg/m2 Days 1, 2, 8, 9, 15, 16 of 
a 28-day cycle. Dexamethasone will be administered at 40 mg Days 1, 8 and 15 
of every cycle. Ruxolitinib to determine maximum tolerated dose (MTD)  will be 
administered orally at 5 , 10 or 15 mg twice daily on D ays 1 -28. Cycles last for 
28 days. 
Phase II/Run -in Period : Carfilzomib at a twice weekly dose of 56mg/m2 and 
dexamethasone  will be  administered following  the Phase I schedule for all 
subjects  who had received a carfilzomib dose less than  the twice weekly dose of 
56mg/m2 prior to study enrollment to assess non- response .   
Note: Subjects who previously received carfilzomib regimen with ≥ 56mg/m2 
will proceed directly to Phase II/Ruxolitinib . 
Non-responders  (after Cycle 1) :  proceed to Phase II /Ruxolitinib . 
 Responders  (after Cycle 1):  carfilzomib -dexamethasone will be administered 
until disease relapse/ progression, at which time they will cross over to 
carfilzomib -dexamethasone- ruxolitinib (Phase II/Ruxolitinib) until disease 
relapse/progression.   
Phase II/Ruxolitinib : Ruxolitinib wi ll be administered orally at MTD  on Days 
1-28 for non-responders until disease relapse/progression. Cycles last for 28 
days. 
Statistical  
Analysis  Kaplan -Meier techniques will be used to estimate overall survival, progression -
free survival , time to progression, time to best response, and duration of 
response . The 4 -month PFS rate will be estimated based on the KM analysis 
with Greenwood’s Formula for the 95% confidence interval . The 4- month 
response rate will be estimated using all enrolled p atients as the denominator 
with the associated 95% confidence interval by the Clopper -Pearson method.  
Safety and toxicity will also be assessed using frequencies and proportions.  
Logistic regression and Cox proportional hazards models will be used to ass ess 
the correlation between biomarkers and efficacy and toxicity outcomes.  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
5 
  
SCHEMA  
 
 
 
 
  

Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
6 
  
 
  
 

Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
7 
 LIST OF ABBREVIATIONS  
Abbreviation  Spelled out abbreviation  
ADL  Activities of daily living  
ADRs  Adverse drug reaction  
AE Adverse event  
ALL  Acute lymphoblastic leukemia  
ANC  Absolute neutrophil count  
AUC  Area under the curve  
BID Twice a day  
BM Bone marrow  
BSA  Body surface area  
BNP  Brain Natriuretic Peptide  
BTZ  Bortezomib  
BUN  Blood urea nitrogen  
CFR  Code of Federal Regulation s 
Cmax  Maximum concentration  
CMP  Good manufacturing practices  
CR Complete response  
CrCl  Creatinine clearance  
CRd Carfilzomib, revlimid, dexamethasone  
CTCAE  Common terminology criteria for adverse events  
CTMS  Clinical Trial Management System  
DCSI  Development core safety information  
DLT  Dose limiting toxicity  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
8 
 DNA  Deoxyribonucleic acid  
DOR  Duration of response  
DSMC  Data and Safety Monitoring Committee  
EBMT  European group for blood and bone marrow criteria  
EC Ethics committee  
ECHO  Echocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  Electronic case report form 
EOT  End of treatment  
FDA  Food and Drug Administration  
FLC Free light chain  
FOCBP  Females of child bearing potential  
GCP  Good clinical practice  
GMP  Good manufacturing practice  
HA Health authority  
HBV  Hepatitis B Virus  
HDT  High dose therapy  
HIV Human immunodeficiency virus  
IMiD  Immunomodulatory agent 
INR International normalized ratio  
IMWG  International Myeloma Working Group  
IRB Institutional Review Board  
IV Intravenously  
JAK Janus kinase  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
9 
 LCI Levine Cancer Institute  
LDH  Lactate dehydrogenase  
LVEF  Left ventricular ejection fraction  
MM Multiple myeloma  
MR Minimum response  
MTD  Maximum tolerated dose  
MUGA  Multi gated acquisition scan  
NCI National Cancer Institute  
ORR  Overall response rate  
OS Overall survival  
PBMC  Peripheral blood mononuclear cell 
PCR  Polymerase chain reaction  
PET/CT  Positron emission tomography/ computed tomography  
PFS Progression free survival  
PI Protease inhibitor  
PO By mouth  
POEMS  Polyneuropathy organomegaly endocrinopathy monoclonal gammopathy  and 
skin changes  
RNA  Ribonucleic acid  
RRMM  Relapsed refractory multiple myeloma  
SAE  Serious adverse event  
SCLC  Small cell lung cancer  
SGOT  Serum glutamatic oxaloacetic transaminase  
SGPT  Serum glutamatic pyruvic transaminase  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
10 
 SIFE  Serum immunofixation electrophoresis  
SNP Single nucleotide polymorphism  
STATs  Signal transducers and activator of transcription  
TLS Tumor lysis syndrome  
TTP Time to progression  
UIFE  Urine immunofixation electrophoresis  
UPEP  Urine protein electrophoresis  
UPP Ubiquitin -proteasome pathway  
 
  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
11 
 TABLE OF CONTENTS  
 
PROTOCOL SUMMARY ........................................................................................................... 3 
SCHEMA  ....................................................................................................................................... 5 
LIST OF A BBREVIATIONS…………………………………………………………………...7 
1 OBJECTIVES  .................................................................................................................. 14 
1.1 Primary Objectives  ......................................................................................................... 14 
1.2 Secondary Objectives  ..................................................................................................... 14 
1.3 Exploratory Objectives  ................................................................................................... 14 
2 BACKGROUND AND RATIONALE  ........................................................................... 14 
2.1 Study Disease  ................................................................................................................. 14 
2.2 Carfil zomib ..................................................................................................................... 15 
2.3 Dexamethasone  .............................................................................................................. 19 
2.4 Ruxolitinib  ...................................................................................................................... 20 
2.5 Background/Study Rationale  ......................................................................................... 21 
3 Subject SELECTION  ...................................................................................................... 22 
3.1 Accrual  ........................................................................................................................... 22 
4 INVESTIGATIONAL PLAN ......................................................................................... 24 
4.1 Milestone Date Definitions  ............................................................................................ 24 
4.2 Overall Study Design  ..................................................................................................... 25 
4.3 Subject Enrollment  ......................................................................................................... 30 
5 STUDY TREATMENT  ................................................................................................... 31 
5.1 Carfilzomib ..................................................................................................................... 31 
5.2 Dexameth asone Dosage and Administration ................................................................. 34 
5.3 Ruxolitinib Dosage and Administration ......................................................................... 35 
5.4 Treatment Compliance  ................................................................................................... 36 
5.5 Duration of Therapy  ....................................................................................................... 36 
5.6 Drug Accountability ....................................................................................................... 37 
6 DOSE MODIFICATIONS  .............................................................................................. 37 
6.1 Phase I and Phase II Dose Modification and Dose Delay  .............................................. 37 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
12 
 6.2 Dose Reduction Steps ..................................................................................................... 38 
6.3 Dose Modification Guidelines for Carfilzomib and Ruxolitinib during a Cycle of 
Therapy ...................................................................................................................................... 38 
6.4 Dose Modification Guidelines for Dexamethasone  ....................................................... 41 
6.5 Criteria for Initiation of a New Cycle of Therapy  .......................................................... 42 
7 Concomitant Medications  ............................................................................................... 42 
7.1 Required Concomitant Therapy  ..................................................................................... 42 
7.2 Recommended/Allowed Concomitant Therapy  ............................................................. 43 
7.3 Contraindicated Concomitant Therapy  .......................................................................... 43 
8 STUDY PROCEDURES  ................................................................................................. 43 
8.1 Registration  .................................................................................................................... 44 
8.2 Informed  Consent  ........................................................................................................... 44 
8.3 Screening Procedures  ..................................................................................................... 44 
8.4 On Study Procedures:  ..................................................................................................... 45 
8.5 End of Treatment  ............................................................................................................ 46 
8.6 Follow-Up ...................................................................................................................... 47 
8.7 Off-Study  ........................................................................................................................ 47 
9 ADVERSE EVENTS  ....................................................................................................... 48 
9.1 Adverse Event  ................................................................................................................ 48 
9.2 Serious Adverse Event (SAE):  ....................................................................................... 48 
9.3 Overlapping Toxiciti es ................................................................................................... 49 
9.4 Adverse Event Reporting ............................................................................................... 49 
9.5 Abnormal Laboratory Values Defined as AEs  ............................................................... 49 
9.6 Adverse Event Grading  .................................................................................................. 50 
9.7 Adverse Event Attribution ............................................................................................. 50 
9.8 Communication between Investigational Sites  .............................................................. 51 
10 SAFETY DATA COLLECTION, RECORDING AND REPORTING ...................... 51 
10.1  SAE/Pregnancy and Lactation Reporting t o Sponsor -Investigator  ................................ 51 
10.2  SAE Reporting to the FDA  ............................................................................................ 51 
10.3  SAE Reporting by Sponsor -Investigator to Amgen and Incyte  ..................................... 52 
10.4  Safety Reporting to the IRB  ........................................................................................... 54 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
13 
 11 DATA AND SAFETY MONITORING PLAN ............................................................. 54 
12 MEASUREMENT OF EFFECT .................................................................................... 55 
12.1  Timing of Response Evaluation ..................................................................................... 55 
12.2  Response Criteria:  .......................................................................................................... 55 
12.3  Measurable Disease:  ....................................................................................................... 55 
13 STATISTICAL CONSIDERATIONS  ........................................................................... 55 
13.1  Sample Size .................................................................................................................... 55 
13.2  Endpoint Defini tions  ...................................................................................................... 56 
13.3  Analysis Populations  ...................................................................................................... 58 
13.4  Analysis Methods  ........................................................................................................... 59 
13.5  Interim Analyses  ............................................................................................................ 61 
14 STUDY COMPLETION ................................................................................................. 61 
14.1  Completion  ..................................................................................................................... 61 
14.2  Termination  .................................................................................................................... 62 
15 Ethical a nd Legal Issues  .................................................................................................. 62 
15.1  Retention of Records  ...................................................................................................... 62 
15.2  Ethical and Legal Conduct of the Study......................................................................... 62 
15.3  Confidentiality  ................................................................................................................ 63 
16 PUBLI CATION POLICY ............................................................................................... 63 
17 REFERENCES  ................................................................................................................. 65 
18 APPENDICES  .................................................................................................................. 68 
18.1  ECOG Performance Scale .............................................................................................. 68 
18.2  NCI CTCAE VERSION 4.03 ......................................................................................... 69 
18.3  Response Criteria for Multiple Myeloma ....................................................................... 69 
18.4  Estimated Creatinine Clearance rate (eCCr) using Cockcroft -Gault Formula  ............... 74 
18.5  Table of Events ............................................................................................................... 75 
 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
14 
 1 OBJECTIVES  
1.1 Prim ary Objectives  
1.1.1 Phase I  
The primary objective of Phase I is to establish the maximum tolerated dose ( MTD ) of 
ruxolitinib  in combination with carfilzomib  and dexamethasone in relapsed refractory 
multiple myeloma.  
1.1.2 Phase II 
The primary objective  of the Phase II segment of this study is  to evaluate the 4- month 
progression free survival rate ( PFS4) in subjects  who receive the combination treatment 
carfilzomib,  dexamethasone and ruxolitinib. 
1.2 Secondary Objectives  
Secondary objectives include evaluation of objective response rate (ORR), clinical benefit 
rate, disease control rate, progression- free survival, time to best response, overall surv ival, 
time to progression and duration of response  in subjects  that receive treatment with the 
triple  drug combination, and further evaluat ion of  the safety and tolerability of the 
combination of c arfilzomib, dexamethasone and ruxolitinib (Phase I ) and carfilzomib, 
dexamethasone +/ - ruxolitinib ( Phase II) .  
1.3 Exploratory Objectives  
Exploratory objectives include the following:  
• Explore the correlation of serum cytokine profile with toxicities and treatment response  
• Explore the correlation of PBMC proteasome and JAK inhibition with toxicities and 
treatment response  
• Examine changes in biology of BM and BM plasma cells before and after treatment by 
RNA sequenc ing 
2 BACKGROUND AND RATIONALE  
2.1 Study Disease  
Multiple myeloma (MM) is a neoplasm of plasma cells that is characterized by osteolytic bone 
lesions and organ damage, such as hypercalcemia, anemia, and renal insufficiency.  Despite major 
advances in therapy, MM is still considered an incurable malignancy.  While the introduction of 
immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs), and advances in high dose 
therapy (HDT) administration have made an impact on PFS and OS  for MM patients in general, 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
15 
 the majority of patients suffer relapses with progressively shorter disease- free intervals with each 
relapse.  Therefore, it is imperative to identify the  patients at high -risk of disease relapse and 
develop novel therapeutic regimens that extend progression free survival (PFS) and overall 
survival (OS) in this group of MM patients.  
2.2 Carfilzomib  
2.2.1 Carfilzomib Indication  
Carfilzomib  is a proteasome inhibitor indicated in combination with dexamethasone or with 
lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory 
multiple myeloma who have received one to three lines of therapy. Carfilzomib is also i ndicated 
as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy. Approval is based on response rate.  Clinical benefit, 
such as improvement in survival or symptoms, has not been verified.  
2.2.2 Clinical Pharmacology  
Mechanism of Action  
 
Carfilzomib is a tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds to the N -
terminal threonine -containing active sites of the 20S proteasome, the proteolytic core particle 
within the 26S proteasome.  Carfilzomib had antiproliferative and proapoptotic activities in vitro 
in solid and hematologic tumor cells.  In animals, carfilzomib inhibited proteasome activity in blood and tissue and delayed tumor growth in models of multiple m yeloma, hematologic, and 
solid tumors . 
Pharmacodynamics  
 
Intravenous carfilzomib administration resulted in suppression of proteasome chymotrypsin- like 
activity when measured in blood 1 hour after the first dose.  On Day 1 of Cycle 1, proteasome inhibition  in peripheral blood mononuclear cells ( PBMCs ) ranged from 79% to  89% at 15 
mg/m2, and from 82% to 83% at 20 mg/m2.  In addition, carfilzomib administration resulted in inhibition of the LMP2 and MECL1 subunits of the immunoproteasome ranging from 26% to 32% and 41% to 49%, respectively, at 20 mg/m2.  Proteasome inhibition was maintained for ≥ 48 hours following the first dose of carfilzomib for each week of dosing.
 
Pharmacokinetics  
 
Absorption:  The Cmax  and AUC following a single intravenous dose of 27 mg/m2 was  4232 
ng/mL and 379 ng•hr/mL, respectively.  Following repeated doses of carfilzomib at  15 and 20 
mg/m2, systemic exposure (AUC) and half -life were similar on Days 1 and 15 or  16 of Cycle 1, 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
16 
 sugge sting there was no systemic carfilzomib accumulation.  At doses between 20 and 36 
mg/m2, there was a dose -dependent increase in exposure.  
Distribution:  The mean steady -state volume of distribution of a 20 mg/m2 dose of carfilzomib 
was 28 L.  When tested in vitro, the binding of carfilzomib to human plasma proteins averaged 
97% over the concentration range of 0.4 to 4 micromolar. 
Metabolism: Carfilzomib was rapidly and extensively metabolized.  The predominant 
metabolites measured in human plasma and urine, and generated in vitro by human hepatocytes, 
were peptide fragments and the diol of carfilzomib, suggesting that peptidase cleavage and 
epoxide hydrolysis were the principal pathways of metabolism.  Cytochrome P450- mediated 
mechanisms played a minor role i n overall carfilzomib metabolism.  The metabolites have no 
known biologic activity. 
Elimination: Following intravenous administration of doses ≥ 15 mg/m2, carfilzomib was 
rapidly cleared from the systemic circulation with a half -life of ≤ 1 hour on Day 1 of  Cycle 1. 
The systemic clearance ranged from 151 to 263 L/hour, and exceeded hepatic blood flow, suggesting that carfilzomib was largely cleared extrahepatically.  The pathways of  carfilzomib 
elimination have not been characterized in humans. 
Age: Analysis of population pharmacokinetics data after the first dose of Cycle 1 (Day 1) in 154 
patients who had received an IV dose of 20 mg/m2 showed no clinically significant difference in 
exposure between patients < 65 years and ≥ 65 years of age.  
Gender:  Mean dose -normalized AUC and Cmax values were comparable between male and 
female patients in the population pharmacokinetics study. 
Hepatic Impairment:  The pharmacokinetics and safety of carfilzomib  were evaluated in 
patients with advanced malignancies w ho had either normal hepatic function, or mild (bilirubin > 
1 to 1.5 × ULN or AST > ULN), moderate (bilirubin > 1.5 to 3 × ULN), or severe (bilirubin > 3 
× ULN) hepatic impairment. The AUC of carfilzomib increased by approximately 50% in 
patients with mild  and moderate hepatic impairment compared to patients with normal hepatic 
function. PK data were not collected in patients with severe hepatic impairment. The incidence of serious adverse events was higher in patients with mild, moderate , and severe hepati c 
impairment combined (22/35 or 63%) than in patients with normal hepatic function (3/11 or 
27%).  
 
Renal Impairment: A pharmacokinetic study was conducted in which 43 multiple myeloma 
patients who had various degrees of renal impairment and who were class ified according to their 
creatinine clearances (CLcr) into the following groups:  normal function (CLcr  > 80 mL/min, n = 
8), mild impairment (CLcr 50 –80 mL/min, n = 12), moderate impairment  (CLcr 30 –49 mL/min, 
n = 8), severe impairment (CLcr < 30 mL/min, n = 7), and chronic dialysis (n = 8).  C arfilzomib  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
17 
 was administered intravenously over 2 to 10 minutes, on two consecutive days, weekly for three 
weeks (Days 1, 2, 8, 9, 15, and 16), followed by a 12- day rest period every 28 days.  Patients 
received an initial dose of 15 mg/m2, which could be escalated to 20 mg/m2 starting in Cycle 2 
if 15 mg/m2 was well tolerated in Cycle 1.  In this study, renal function status had no effect on 
the clearance or exposure of carfilzomib  following a single or repeat -dose administration.  
Cytochrome P450:   In an in vitro study using human liver microsomes, carfilzomib showed 
modest direct and time -dependent inhibitory effect on human cytochrome CYP3A4/5.  In vitro 
studies indicated that carfilzomib did not induce human CYP1A2 and CYP3A4 in cultured fresh 
human hepatocytes.  Cytochrome P450- mediated mechanisms play a minor role in the overall 
metabo lism of carfilzomib.  A clinical trial of 17 patients using oral midazolam as a CYP3A 
probe demonstrated that the pharmacokinetics of midazolam were unaffected by concomitant 
carfilzomib administration.  C arfilzomib  is not expected to inhibit CYP3A4/5 acti vities and/or 
affect the exposure to CYP3A4/5 substrates.  
P-gp: Carfilzomib is a P -glycoprotein (P -gp) substrate and showed marginal inhibitory effects on 
P-gp in a Caco -2 monolayer system.  Given that carfilzomib  is administrated intravenously and 
is ext ensively metabolized, the pharmacokinetic profile of carfilzomib  is unlikely to be affected 
by P-gp inhibitors or inducers.  
2.2.3 Nonclinical Toxicology  
Carcinogenesis, M utage nesis, an d Impairment of Fertility  
 
Carcinogenicity studies have not been conducted with carfilzomib.  
Carfilzomib was clastogenic in the in vitro chromosomal aberration test in peripheral blood 
lymphocytes.  Carfilzomib was not mutagenic in the in vitro bacterial reverse mutation (Ames) test and was not clastogenic in the in vivo mouse bone marrow micronucleus assay.  
Fertility studies with carfilzomib have not been conducted.  No effects on reproductive tissues 
were noted during 28- day repeat -dose rat and monkey toxicity studies or in 6- month rat and 9-
month monkey chronic toxicity studies.  
2.2.4 Clinical Studies  
The carfilzomib clinical investigation program began in September 2005.  Carfilzomib is currently being investigated  for potential treatment of both hematologic and solid tumor 
malignancies , but not necessarily being develop ed in the solid tumor setting .  
As discussed below, the clinical development of carfilzomib initially focused on patients with 
relapsed and refractory multiple myeloma, assessing carfilzomib as monotherapy in these 
patients with few therapeutic options.  S ubsequently, carfilzomib is being evaluated as a 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
18 
 component of combination therapy for treatment in earlier lines of therapy for patients with 
multiple myeloma, including newly diagnosed multiple myeloma  patients.  The clinical program 
has also expanded to include investigation in solid tumors (e.g., small cell lung cancer lung 
cancer [SCLC]) and pediatric acute lymphoblastic leukemia (ALL) , but not necessarily 
developed in these settings . 
Initia l Clinica l Developmen t – Carfilzomib as Monotherapy  
 
Carfilzomib for Injection was  originally  approved in 2012 in the United States (US) (brand name 
Kyprolis) under the US Food and Drug Administration’s (FDA) accelerated approval program 
for the treatment of patients with relapsed and refractory multiple mye loma who have received at 
least 2 prior therapies, including bortezomib and an immunomodulatory drug (IMiD), and have 
demonstrated disease progression on or within 60 days of completion of the last therapy.  
Accelerated approval in the US, w as based on the results of the single -arm Phase II  study PX -
171-003 – Part 2 (A1) where an ORR  of 23.7%, DOR of 7.8 months, PFS  of 3.7 months, and OS  
of 15.4 months were observed.  The approved carfilzomib dose is 20 mg/m2 during Cycle 1, and if tolerated, th e dose is increased to 27 mg/m2 during Cycle 2, given twice weekly for 3 of every 
4 weeks (Days 1, 2, 8, 9, 15, and 16), with infusion durations of 2 to 10 minutes.  In an even 
more advanced and refractory population, the Phase III Study PX -171-011 (FOCUS)  did not 
meet the primary objective of demonstrating superiority of carfilzomib monotherapy over the 
active doublet therapy in the control arm (corticosteroids and optional cyclophosphamide) in OS 
(hazard ratio [HR] = 0.975 [95% confidence interval (CI):  0.760–1.249], 1- sided p- value = 
0.4172).  The median OS with carfilzomib monotherapy was 10.2 months versus 10.0 months for active control.  The PFS was similar in both study arms of PX -171-011 (carfilzomib 
monotherapy 3.7 months versus active control arm 3.3 months, HR = 1.091 [95% CI:  0.843–
1.410]).  
Subsequen t Clinica l Developmen t – Carfilzomib in Combination Therapy   
The efficacy observed in the monotherapy program supported the development of carfilzomib in 
combination with lenalidomide and low -dose de xamethasone, based on the hypothesis that this 
combination may result in the ability to deliver optimized proteasome inhibition leading to 
improved efficacy.  Results from the randomized, pivotal, Phase III Study PX -171-009 
(ASPIRE) demonstrated that carfi lzomib in combination with lenalidomide (Revlimid) and low -
dose dexamethasone (CRd) in subjects with relapsed multiple myeloma has unprecedented efficacy with an 8.7- month  improvement  in median  PFS when compared with (Revlimid) 
lenalidomide with low -dose dexamethasone (Rd) (HR = 0.69), and a median PFS of 26.3 months 
with CRd treatment.  
Current  Status  of Carfilzomib  Clinical  Development  
 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
19 
 As of 19 July 2019, approximately 4508 individual subjects have been treated with carfilzomib 
as participants of Amgen -sponsored clinical studies.  As of 31 July 2019, approximately 6582 
subjects have received carfilzomib in investigator -sponsored trials.   
A thorough and comprehensive assessme nt of carfilzomib safety was conducted by Amgen with 
safety information available from a large clinical development program. Important adverse drug 
reactions (ADRs) identified based on a comprehensive analysis of safety data from all relevant 
sources, incl uding clinical studies  and the Amgen Global S afety D atabase have been well -
characterized.   There was no evidence of cumulative or new -onset toxicity with prolonged 
exposure to carfilzomib. Overall, the safety and efficacy data from the clinical program support continued development of carfilzomib in subjects with multiple myeloma  and expansion to the 
pediatric ALL population.  
2.3 Dexamethasone  
2.3.1 Description  
Dexamethasone (Decadron) is a synthetic adrenocortical steroid and is readily absorbed from the gastrointestinal tract.  Chemically, dexamethasone is 9 -fluoro -11b, 17, 21- trihydroxy- 16a-methyl -
pregna -1, 4-diene -3, 20- dione. 
2.3.2 Toxicology 
Human Toxicology:  Possible adverse effects associated with the use of dexamethasone are:  
fluid and electrolyte disturbances, congestive heart failure in susceptible persons, hypertension, 
euphoria, personality changes, insomnia, exacerbation of infection (e.g., tuberculosis), 
exacerbation or symptoms of diabetes, psychosis, muscle weakness, osteoporosis, vertebral 
compression fractures, pancreatitis, esophagitis, peptic ulcer, dermatologic disturbances, convulsions, vertigo and headache, endocrine abnorma lities, ophthalmic changes, and metabolic 
changes.  Some patients have experienced itching and other allergic, anaphylactic or other 
hypersensitivity reactions.  Withdrawal from prolonged therapy may result in symptoms 
including fever, myalgia and arthralgia.  Phenytoin, phenobarbital and ephedrine enhance 
metabolic clearance of corticosteroids.  
Corticosteroids should be used cautiously in patients with hypothyroidism, cirrhosis, ocular 
herpes simplex, existing emotional instability or psychotic tendencies, nonspecific ulcerative 
colitis, diverticulitis, fresh intestinal anastomoses, peptic ulcer, renal insufficiency, hypertension, 
osteoporosis and myasthenia gravis.   
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
20 
 2.3.3 Pharmacology 
Kinetics:   Natural and synthetic glucocorticoids are readily and completely a bsorbed from the 
GI tract.  Dexamethasone is insoluble in water.  Glucocorticoids have salt -retaining properties, 
although dexamethasone nearly completely lacks this property.  Dexamethasone may suppress 
the body's response to viral and bacterial infections.   
2.4 Ruxolitinib  
2.4.1 Mechanism of Action  
Ruxolitinib, a kinase inhibitor, inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2 which 
mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function.  JAK signaling involves recruitment of STATs (signal 
transducers and activators of transcription) to cytokine receptors, activation and subsequent 
localization of STATs to the nucleus leading to modulation of gene expression. 
2.4.2 Pharmacodynamics  
Ruxolitinib in hibits cytokine induced STAT3 phosphorylation in whole blood from healthy 
subjects and MF patients.  Ruxolitinib  administration resulted in maximal inhibition of STAT3 
phosphorylation 2 hours after dosing which returned to near baseline by 10 hours in both healthy 
subjects and myelofibrosis patients. 
2.4.3 Pharmacokinetics  
Absorption  
In clinical studies, ruxolitinib  is rapidly absorbed after oral administration with maximal plasma 
concentration (Cmax) achieved within 1 to 2 hours post -dose.  Based on a mass balance study in 
humans, oral absorption of ruxolitinib was estimated to be at least 95%.  Mean ruxolitinib Cma x 
and total exposure (AUC) increased proportionally over a single dose range of 5 to 200 mg. There 
were no clinically relevant changes in the pharmacokinetics of ruxolitinib upon administration 
with a high- fat meal, with the mean Cmax moderately decreased (24%) and the mean AUC nearly 
unchanged (4% increase). 
Distribution  
The apparent volume of distribution of ruxolitinib at steady- state is 53 to 65 L in myelofibrosis 
patients.  Binding to plasma proteins in vitro is approximately 97%, mostly to albumin. 
 
Metabolism  
In vitro studies suggest that ruxolitinib is metabolized by CYP3A4 and to a lesser extent by 
CYP2C9.  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
21 
  
Elimination  
Following a single oral dose of [14C] -labeled ruxolitinib in healthy adult subjects, elimination 
was predominately through metabolis m with 74% of radioactivity excreted in urine and 22% 
excretion via feces.  Unchanged drug accounted for less than 1% of the excreted total 
radioactivity.  The mean elimination half -life of ruxolitinib is approximately 3 hours and the 
mean half -life of rux olitinib + metabolites is approximately 5.8 hours . 
2.4.4 Clinical Studies i n Myeloproliferative Neoplasms  
Two randomized Phase III studies (Studies 1 and 2) were conducted in patients with myelofibrosis 
(either primary myelofibrosis, post -polycythemia vera myelofibrosis or post -essential 
thrombocythemia -myelofibrosis).  In both studies, patients had palpable splenomegaly at least 5 
cm below the costal margin and risk category of intermediate 2 (2 prognostic factors) or high risk 
(3 or more prognostic factors) based on the International Working Group Consensus Criteria 
(IWG).  
The starting dose of ruxolitinib  was based on platelet count . Patients with a platelet count between 
100 and 200 X 109/L were started on ruxolitinib  15 mg twice daily and patients with a platelet 
count greater than 200 X 109/L were started on r uxolitinib  20 mg twice daily.  Doses were then 
individualized based upon tolerability and efficacy with maximum doses of 20 mg twice daily for 
patients with platelet counts between 100 to less than or equal to 125 X 109/L  of 10 mg twice daily 
for patients with platelet counts between 75 to less than or equal to 100 X 109/L, and of 5 mg 
twice daily for patients with platelet counts between 50 to less than or equal to 75 X 109/L. 
2.4.5 Clinical Studies in Multiple Myeloma  
There is pre- clinical data1 (Burger R et al, AS CO 2012) that demonstrates  direct cytotoxic effects 
of ruxolitinib  on JAK -STAT pathway dependent cell lines and IL -6 mediated dexamethasone 
resistance could be reversed by addition of ruxolitinib.  
2.5 Background /Study Rationale  
The ubiquitin- proteasome pathway (UPP) is responsible for  the vast majority of regulated 
intracellular proteolysis1 and has been best validated as a target for cancer therapy in MM2 -Pre-
clinical2-8 and clinical studies  9-19 have led to regulatory approvals of the PIs bortezomib and 
carfilzomib.  Plasma cells are  uniquely sensitive to PIs since the UPP capacity for protein 
turnover is impaired during their differentiation, creating an unfavorable match between proteasome load and capacity
20.  This balance has been proposed as a determinant of the 
apoptotic sensiti vity to PIs, with plasma cells having a low protein load and/or high proteasome 
capacity showing relative resistance, while a high load and/or low capacity confers sensitivity21.  
In the clinic, the PIs are used in virtually all patients22-26.  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
22 
 Despite the ir demonstrated benefits, response rates to bortezomib or carfilzomib in unselected 
patients in the relapsed and/or refractory settings are less than 50%17-18 and 25%21-23, 
respectively, and their use is associated with substantial toxicities and cost.  Moreover, virtually 
all patients who initially respond eventually develop disease that is refractory to further PI -based 
therapy through poorly defined mechanisms. 
The current P hase I/II study of carfilzomib, ruxolitinib  and low -dose dexamethasone  is to 
evaluate the potential to overcome PI resistance in RRMM who h ave previously relapsed or 
progressed on carfilzomib.   
The primary purpose of this trial is to determine if the combination of carfilzomib, ruxolitinib 
and low -dose dexamethasone improve s the 4- month progression free survival rate compared to 
historical controls.  
3 SUBJECT  SELECTION  
3.1 Accrual  
This trial will enroll subjects  with a diagnosis of relapsed or relapsed -refractory MM. Up to 18 
DLT  evaluable subjects  will be enrolled in Phase I with 3 dose levels of ruxolitinib to be tested.  
Up to an additional 30 PFS4  evaluable subjects  may be enrolled in the Phase II part at  the MTD 
determined in Phase I. 
All races and ethnic groups are eligible for this study. 
3.1.1 Inclusion Criteria  
Subjects must meet all the following c riteria:  
1. Documented history of relapsed and/ or refractory multiple myeloma with > 2 lines of 
therapy . One of the prior lines of therapy must have been a carfilzomib  containing 
regimen  with  evidence of relapse or progression within the last 60 days of the carfilzomib  
containing regimen  with a carfilzomib dose of at least 27 mg/m2. Carfilzomib containing 
regimen at the standard dose of 20/ 27 mg/m2 is acceptable.  
2. Measurable disease, as defined by at least one of the following:  
a. Serum monoclonal protein level ≥0.5 g/dL for IgG, IgA, or IgM disease  
b. Urinary M -protein excretion of ≥200 mg over a 24 -hour period  
c. Involved free light chain level ≥10 mg/dL, along with an abnormal free light 
chain ratio  
3. Adequate  bone marrow reserves, as defined by the following:  
a. Absolute neutrophil count (ANC) ≥  1000 cells/mm3 within 1 week of the 
initiation of treatment. G -CSF may not have been administered within 7 days of 
Cycle 1 Day.  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
23 
 b. Platelet count of ≥ 75 ,000 cells/mm3 for subjects who have bone marrow 
plasmacytosis of <50%, or ≥ 50,000 cells/mm3 for subjects  who have bone 
marrow plasmacyt osis of ≥ 50%  
4. Adequate hepatic function, as defined by the following:  
a. Total bilirubin ≤2 times the upper limit of the institutional normal values  
b. Total AST and ALT ≤3 times the upper limit of the institutional normal values  
5. Adequate renal function, as defined by the following: creatinine clearance (CrCl) ≥30 
mL/min., as measured by a 24- hour urine collection, or estimated by the Cockcroft and 
Gault formula.  
6. Adequate cardiac function defined as LVEF ≥  40% by MUGA, echocardiogram  or 
cardiac MRI .  
7. Be 18- 75 years of age  
8. Eastern Cooperative Oncology Group (ECOG) performance status of 0–2.  
9. FOCBP  and male subjects who are sexu ally active with F OCBP must agree to use two  
highly effective  (as determined per the Investigator)  methods  of contraception during the 
study and for 30 days  (female subjects) or for 90 days  (male subjects)  following the last 
dose of study treatment including a male condom.  
10. Written informed consent and HIP AA authorization for release of personal health 
information signed by the subject or his/her legally authorized representative . 
11. Recovered from all reversib le acute toxic effects of prior therapy (other than alopecia) to 
≤ Grade 1 or baseline.  
3.1.2 Exclusion Criteria  
Subjects must not meet  any of the following criteria:  
1. Non-secretory multiple myeloma  
2. Known amyloidosis  
3. Known POEMS syndrome (plasma cell dyscrasia w ith polyneuropathy, organomegaly, 
endocrinopathy, monoclonal protein, and skin changes)  
4. Clinically significant illness including, but not limited to the following: active systemic 
infection, uncontrolled hypertension (as defined by BP > 160/90) , New York Heart 
Association Class III and IV heart failure, unstable angina pectoris, myocardial inf arction 
within the past 6 months  of consent , uncontrolled cardiac arrhythmia, or any other 
condition (including laboratory abnormalities) that, in the opinion of the Investigator, 
places the subject at unacceptable risk for adverse outcome if he/she were t o participate 
in the study 
5. Prior cerebrovascular accident with persistent neurologic deficit. 
6. Psychiatric illness/social situations that would limit compliance with study treatment  and 
requirements  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
24 
 7. Pregnant or breast feeding. Females of childbearing potent ial (FOCBP) must have a 
negative serum pregnancy test within the 7 days prior to study drug administration and a 
negative urine pregnancy test within the 3 days prior to the first study drug 
administration .   
8. Known human immunodeficiency virus (HIV) infect ion 
9. Active hepatitis B and/or hepatitis C infection  
• Subjects with resolved HBV infection (i.e. subjects who are HBsAg negative but 
positive for antibodies to hepatitis B core antigen [anti -HBc] and/or antibodies to 
hepatitis B surface antigen [anti -HBs]) must be screened using real -time 
polymerase chain reaction (PCR) measurement of hepatitis B vir us (HBV) DNA 
levels. Subjects who are PCR positive will be excluded. Exception: subjects with serologic findings suggestive of HBV vaccination (anti -HBs positivity as the only 
serologic marker) and a known history of prior HBV vaccination do not need to be  
tested for HBV DNA by PCR.  
10.  “Currently active” second malignancy, other than non- melanoma skin cancer and 
carcinoma in situ of the cervix, should not be enrolled.  Subjects  are not considered to 
have a “currently active” malignancy if they have completed therapy for a prior 
malignancy, are disease free from prior malignancies for >5 years and  are considered by 
their physician to be at less than 30% risk of relapse.  In addition, subjects  with basal cell 
carcinoma of the skin, superficial carcinoma of the b ladder, carcinoma of the prostate 
with a current PSA value of <0.5 ng/mL, or cervical intraepithelial neoplasia will be 
eligible.  Finally, subjects  who are on hormonal therapy for a history of either prostate 
cancer or breast cancer may enroll, provided t hat there has been no evidence of disease 
progression during the previous three years.  
11. Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize 
carfilzomib).  
12. Contraindication to any of the required concomitant drugs or supportive  treatments or 
intolerance to hydration due to preexisting pulmonary or cardiac impairment including 
pleural effusion requiring thoracentesis or ascites requiring paracentesis.  
13. Known intolerance to carfilzomib.  
14. Co-administration with strong CYP3A4 inhibitors (such as, but not limited to, boceprevir, 
clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, ritonavir, 
mibefradil, nefazodone, nelfinavir, posaconazole, saquinavir, telaprevir, telit hromycin, 
voriconazole) as well as fluconazole (a dual inhibitor of  CYP3A4 and CYP2C9). 
4 INVESTIGATIONAL PLAN 
4.1 Milestone Date Definitions  
Registration date : the date the subject signs the informed consent form . 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
25 
  
Enrollment date : the date of initiation of stu dy treatment  on Cycle 1, Day 1.  For the 
Phase I part of the study, this will be the date of initiation of treatment with carfilzomib,  
dexamethasone and ruxolitinib.  For the Phase I I part of the study, this  is the date of  
initiation of treatment with carf ilzomib and dexamethasone  +/- ruxolitinib .   
 
Treatment discontinuation date : the date the Investigator decides to discontinue the 
subject from study treatment .   
 
4.2 Overall Study Design  
This is an open label , Phase I/II protocol. This study will open as a multi- center study 
being conducted at  Levine Cancer Institute ( LCI) and ad ditional investigational sites .  
Potentially, a total of 18 DLT evaluable subjects will be enrolled on the Phase I portion 
and up to 30 PFS4  evaluable subje cts may  be enrolled on the Phase II portion of this 
study. The study accrual period will be an estimated 36 months.  
4.2.1 Phase I  Design  
Phase I will follow the standard 3 + 3 design with 3 to 6 subjects , depending on dose 
limiting toxicity (DLT) observed, at e ach dose level to be tested.  Up to 3 dose levels will 
be tested.  The overall duration of the Phase I  portion of the study is expected to be no 
longer than 12 months . 
Subjects  will receive carfilzomib  56 mg/m2/day* IV over 30 minutes on Days 1, 2, 8, 9, 
15 and 16 of a 28 day cycle. *Note: Subjects who have received CFZ <  56mg/m2 more 
than 60 days prior to informed consent should receive CFZ 20mg/m2 on Days 1 and 2 of the first cycle of protocol therapy with subsequent doses of 56mg/m
2.   
Dexamethasone is administered orally prior to carfilzomib at 40 mg on D ays 1, 8, and 15 
of a 28 day cycle. Note: a 20 mg dose may be considered for subjects ≥ 75 years of age 
and for diabetic subjects.   
Ruxolitinib  is administered orally with or without food twice daily for 28 days  of a 28 
day cycle  
Table 1: Dose Levels to be T ested  
Cohort  
Each cycle is 28 days  Carfilzomib  
IV over 30 m in Dexamethasone   
PO Ruxolitinib  
PO 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
26 
 Days 1, 2, 8,  9, 15, 16 Days 1, 8 and 15  Twice  Daily Days 1 -28 
Cohort 1 56 mg/m2a 40 mg POb 5 mg 
Cohort 2  
56 mg/m2a 
 40 mg POb 10 mg 
Cohort 3  
56 mg/m2a 
 40 mg POb 15 mg 
 
a. Subjects who have received CFZ < 56mg/m2 more than 60 days prior to informed 
consent should receive CFZ 20mg/m2 on Days 1 and 2 of the first  cycle with 
subsequent doses of 56mg/m2.  See section 4.2.1.1 for MTD guidance  
b. A 20 mg dose may be considered for subjects ≥ 75 years of age and for diabetic  
subjects.  
4.2.1.1 Phase I Dose Escalation Guidelines  
The first cohort of subjects enrolled in the Phase I portion of the study will receive dose level 1.  
A full safety evaluation will be conducted when these subjects  have completed one cycle of 
combination therapy. Based on the evaluation after the first cycle, the dose escalation for 
subsequent subjects  will proceed as follows:  
• If no DLT is reported in the first three subjects  at a dose level, that dose level will be  
considered safe,  and three subjects  will be enrolled at the next higher dose level.  
• If 1 out of 3 subjects  in a cohort at a dose level has a DLT, the dose level will be 
expanded to obtain six evaluable subjects . If 2 or more  subjects  in a cohort  of 6 subj ects 
at a dose level has a DLT, that dose level will not be considered safe, no further dose escalation will take place, and the MTD will have been exceeded*.   
• If there is  at most 1 subject  with a DLT among an expanded cohort of six evaluable 
subjects , that dose level will be considered safe and  a cohort of three subjects  will be 
enrolled in the next higher dose level.  
When the MTD has been exceeded:  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
27 
 If less than 6 subjects  have been treated in the next lower dose level (the possible MTD level), 
additional  subjects  will be entered into this dose level until there are 6 subjects  treated.  If at 
most 1 of these 6 subjects  encountered DLT, then this dose level will be declared to be the MTD.  
If 2 or more of the 6 subjects  encounter DLT, then the MTD has been exceeded.   
NOTE: If a subject  discontinues treatment for reasons unrelated to adverse events such that 
safety in cycle one cannot be fully evaluated, an additional subject may be enrolled; this will be 
reviewed on a case by case basis.  
4.2.1.2 Definition of Maxi mum Tolerated Dose  
The MTD of the combination of c arfilzomib, dexamethasone and ruxolitinib in multiple 
myeloma subjects  shall be defined as the highest dose level resulting in at most 1 out of 6 
subject s experiencing DLT in Cycle 1. The dose will be esca lated in a new cohort until an MTD 
is identified or the maximum planned dose is achieved.  
4.2.1.3 Definition of DLT  
A dose -limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value 
assessed as related or possibly related to  the study reg imen that occurs within the first cycle of 
treatment and meets any of the criteria outlined below. National Cancer Institute CTCAE version 
4.03 will be used for all adverse event grading.  
• Grade 3 or greater non -hematologic toxicity possible/probable/definite ly related 
to treatment.  The following exceptions wil l apply:  
 Grade 3 nausea/vomiting or diarrhea for less than 72 hours with adequate 
antiemetic and other supportive care  
 Grade 3 fatigue for less than 1 week  
 Grade 3 or higher isolated electrolyte abnormalities that last up to 72 
hours, are not clinically complicated, and resolve spontaneously or 
respond to conventional medical interventions  
 Grade 3 or higher amylase or lipase elevation that is not associated with 
symptoms or clini cal manifestations of pancreatitis  
 Grade 3 tumor lysis syndrome (TLS) that lasts up to 72 hours, is not 
clinically complicated, and resolves spontaneously or responds to 
conventional medical interventions  
• Grade 3 -4 thrombocytopenia (platelet count < 50,000/ mm3) with clinically 
significant bleeding.    
• Grade 4 neutropenia must occur for more than 5 days to be considered a DLT.  A 
grade 4 neutropenia with duration of less than or equal to 5 days or grade 3 
neutropenia must result in neutropenic fever with el evated temperature (defined as 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
28 
 ANC < 1000/mm3 with a single temperature of > 38.3°C or sustained temperature 
of ≥ 38°C for more than one hour) to be considered dose -limiting.   
• Other grade 4 hematological toxicity (other than thrombocytopenia, neutropenia , 
leukocytopenia  and lymphopenia)   
The prophylactic use of G-CSF and platelet transfusions in cycle one of the dose escalation 
cohorts in Phase I is not permitted.  
Once the MTD has been determined in Phase I , an additional 30 evaluable subjects  will be 
enrolled and treated at the MTD.  The evaluation of the MTD will be based on the toxicity 
observed during Cycle 1 of Phase I.   
4.2.2 Phase II Design  
 Subjects  in the Phase II/ Run- in period will receive an in itial cycle with carfilzomib at the twice 
weekly dose of 56mg/m2 and dexamethasone.  Following Cycle 1 , a response assessment will be 
done. Subjects with a response of PR or better (“Responders”) will continue therapy with 
carfilzomib and dexamethasone. After these responding subjects subsequently progress, they will be treated with ruxolitinib (at the dose established in Phase 1) in combination with carfilzomib 
and dexamethasone. Subjects with a response of less than PR (“ Non-responders”) will add 
ruxolit inib at the dose established in Phase I to carfilzomib and dexamet hasone for all subsequent 
cycles.  The cycl e when  ruxolitinib is added will be considered Cycle 1 (cycle numbers will start 
over).   Disease evaluation assessment results should be available prior to dosing on Day 1  of 
each cycle of Phase II  until initiation  of ruxolitinib treatment  (to ensure initiation of ruxolitinib 
occurs on Day 1 of a cycle) .  
Enrollment in the Phase II part of the  study will be carried out in two stages .  During the first 
stage, 10 PFS evaluable subjects  (Section 13.3)  will be enrolled .  Enrollment and Stage 1  
analysis of the first ten  subjects  on the three drugs (carfilzomib -ruxolitinib -dexamethasone)  will 
be completed to determine if at least 3 of 10 subjects  are alive and progression free at 4 months.  
If so, an additional 20 subjects  will be enrolled (a total of 30 subjects ) during the second stage.  
If at least 11 of 30 subjects  are alive and progression free at 4 months, the null hypothesis will be 
rejected (based on binomial probabilities , see Secti on 13.1.2).  The overall duration of the Phase 
II portion of the study is expected to be no longer than 24 months .  For both Phase I and Phase II, 
subjects will be assessed for response after each cycle with confirmation of response according 
to IMWG response criteria regardless of dose level treated. Doses of each study drug may be 
interrupted or reduced in an attempt to manage toxicity. 
Table 2: Phase II/Run- In Dosing
a 
Drug  Dose  Route  Schedule  Cycle Length  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
29 
 Dexamethasone  40 mgb PO D1, 8, and 15  
(Prior to 
carfilzomib)   
28 days  
Carfilzomib  56 mg/m2c Intravenously 
(IV) over 30 
minutes  D1, 2, 8, 9, 15, 
and 16 
 
a All subjects en rolled in  Phase II will initiate treatment in the Run -in Phase with the exception of  subjects who 
previously received a carfilzomib regimen (prior to study enrollment) of ≥ 56 mg/m2. These subjects will proceed 
directly to Phase II/Ruxolitinib (see Table 3 ). Subjects will have a disease response assessment prior to Cycle 2 
(results must b e available prior to Day 1 dosing) and will continue treatment in the Run- In until one of the 
following:  
• Determined to be a “Non -responder” after Cycle 1 (defined as < PR per IMWG criteria) OR  
• Determined to be a “Responder” after Cycle 1 (defined as ≥  PR p er IMWG criteria) with subsequent 
disease progression  
After one of the above criteria are met, subjects will move into the Phase II/R uxolitinib Phase (see Table 3 ) 
b A 20 mg dose may be considered for subjects ≥ 75 years of age or for diabetic subjects.  
c Subjects who previously received carfilzomib < 56mg/m2 more than 60 days prior to informed consent should 
receive carfilzomib 20mg/m2 on Days 1 and 2 of the first cycle with subsequent doses of 56mg/m2 
Table 3: Phase II/Ruxolitinib Dosinga  
Drug  Dose  Route  Schedule  Cycle Length  
 
Dexamethasone   
40 mgb  
PO D1, 8, and 15  
Prior to 
carfilzomib  
28 days  
*note: Cycle numbers start 
over at Cycle 1 once 
ruxolitinib is initiated   
Carfilzomib   
56 mg/m2  Intravenously 
(IV) over 30 
minutes  D1, 2, 8, 9, 15, 
and 16 
Ruxolitinib  MTD from 
Phase I  PO Twice d aily 
from C1 D1, 
continuously 
 
a. Subjects enrolled in Phase II will initiate ruxolitinib at one of the following time -points:  
 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
30 
 • Initiated treatment in the Run -In Phase and determined to be a “Non -responder” after Cycle 1  
• Initiated treatment in the Run -In Phase, determined to be a “Responder” after Cycle 1 with subsequent 
disease progression  
• Determined to have received carfilzomib regimen (prior to study enrollment) of ≥ 56 mg/m2. These 
subject s will skip the Run -In Phase and proceed directly to ruxolitinib (in combination with 
carfilzomib and dexamethasone).  
 
b. A 20 mg dose may be considered for subjects ≥  75 years of age or for diabetic subjects  
 
4.3 Subject Enrollment  
Phase I  
Enrolled s ubjects in P hase I will be DLT evaluable if  they experience a DLT during Cycle 1 of 
treatment with the carfilzomib, r uxolitinib and de xamethasone  regimen .  
Enrolled s ubjects in Phase I who do not  experience a DLT  must meet all of  the criteria below to 
be DLT evaluable:  
• complete Cycle 1  of ruxolitinib  therapy  defined as followed 
o initiate Cycle 2 , or 
o discontinue  ruxolitinib therapy prior to Cycle 2 if the discontinuation date (as 
defined in Section 4.1) is on Cycle 1 Day 25 or later     
• return no more than 20% of the number of ruxolitinib pills prescribed for Cycle 1 (while 
taking into account the actual length of Cycle 1)  
• do not receive G-CSF or platelet transfusions  during Cycle 1  
 
Subjects who discontinue study treatment without experiencing a DLT and do not meet the DLT 
criteria as stated above will not be included in the 3+3 MTD evaluation but  will be included in 
the overall analyses.  Enrollment of new subjects  to the current cohort will only be considered if 
there is less than the required number of DLT evaluable subjects  to determine toxicity for the 
cohort.  For example , of 3 subjects  in a cohort, one withdraws due to disease progression, but 2 
others have DL T, there is no need to continue enrollment to the given cohort as the MTD has 
already been exceeded.  Alternatively , of 3 subjects  in a cohort, one withdraws due to disease 
progression, but 2 others have not experienced a DLT, enrollment to the cohort will continue to 
fully evaluate the cohort with three DLT evaluable subjects ).   
Phase II 
All enrolled subjects will remain in the intent to treat population.  Enrollment to the Phase II part 
of the study will continue until the sample size requirements for the PFS 4 evaluable population 
are achieved  (Section 13.3) .   
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
31 
 5 STUDY TREATMENT  
Treat ment will be administered on an outpatient basis.  Reported adverse events and potential  
risks are described in the Investigational Brochure and Prescribing Information.  Appropriate 
dose modifications are described in Section 6.  
The study drugs  must be e xclusively used for the investigation specified in this protocol and will 
only be accessible to authorized staff.  
5.1 Carfi lzomib  
5.1.1 Carfilzomib Dose  
Subjects  will receive carfilzomib 56  mg/m2/day IV over 30 minutes on Days 1, 2, 8, 9, 15 and 16 
of a 28 -day cycle .  Subjects who have received CFZ < 56mg/m2 more than 60 days prior to 
informed consent should receive CFZ 20mg/m2 on Days 1 and 2 of the first cycle  of carfilzomib  
with subsequent doses of 56mg/m2.   
 
The dose will be calculated using the subject’s actual BSA at baseline.  Subjects with a BSA > 2.2 m
2 will receive a dose based upon a 2.2 m2 BSA.  Dose adjustments do not need to be made 
for weight changes of less than or equal to 20%  from baseline weight . 
5.1.2 Carfilzomib Administration  
5.1.2.1 Hydration  and Fluid Monitoring  
• At least 48 hours before the first dose of carfilzomib , oral hydration should be given as 
follows:  30 mL/kg/day (approximately 6 to 8 cups of liquid per day) continuing up to the time of treatment.  Subject compliance must be assesse d before initiating treatment, 
which is to be delayed if oral hydration is not adequate.  In subjects considered at risk for TLS, oral hydration should be continued in Cycle 2 and beyond as required by the 
subject’s medical condition and at the Investigator’s discretion . 
• IV hydration will be given immediately prior to carfilzomib during the first cycle of 
carfilzomib .  This will consist of 250 to 500 mL normal saline or other appropriate IV 
fluid. Co -morbidities should be considered when determining the appropriate volume of 
fluid to administer (e.g. consider 250 ml for subjects with increased cardiac risk). If 
lactate dehydrogenase (LDH) or uric acid is elevated (and/or in subjects considered still 
at risk for TLS) at the completion of the first cycle of ca rfilzomib ( Cycle 2 Day 1 ), then 
the recommended IV hydration should be given additionally before each dose in the 
second cycle.  The goal of the hydration program is to maintain robust urine output (e .g. 
≥ 2 L/day).  Subjects should be monitored periodical ly during this period for evidence of 
fluid  overload.  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
32 
 • If the subject has a dedicated line for carfilzomib administration, the line must be flushed 
with a minimum of 20 mL of normal saline prior to and after drug administration.    
5.1.2.2 Carfilzomib Infusion  
• Carfilzomib will be given as an IV infusion over approximately 30 minutes.  The dose 
will be administered at a facility capable of managing hypersensitivity reactions.  
Subjects will remain at the clinic  under observation for at least 1 hour following each 
dose of carfilzomib in  the first cycle of carfilzomib .  During these observation times, post 
dose IV hydration (between 250 mL and 500 mL normal saline or other appropriate IV 
fluid formulation)  is recommended but will be administered per the investigator’s 
discretion  .  Subjects should be monitored periodically during this period for evidence of 
fluid overload.  
5.1.3 SAFETY CONSIDERATIONS  
• A “first dose effect” has been seen, which is notable for fever,  chills, rigors, and/or 
dyspnea occurring during the evening following the first day of infusion and an increase in creatinine on Day 2, which may be the clinical sequelae of rapid tumor lysis and/or cytokine release.    
• Should a “first dose” effect occur at any point during the first or second cycle of 
carfilzomib , treatment with high dose glucocorticoids (e.g. methylprednisolone 50–100 
mg) is recommended.  In addition, intravenous fluids, vasopressors, oxygen, bronchodilators, and acetaminophen should be available and instituted, as medically indicated.  
• Acyclovir or similar should be given to all subjects, per institutional prophylaxis 
guidelines, unless contraindicated.  
• For subjects who are carriers of HBV, prophylaxis with antivirals should be considere d. 
• CrCl  changes are mostly transient, reversible, and non- cumulative. All subjects should be 
well hydrated.  Clinically significant electrolyte abnormalities should be corrected prior 
to dosing with carfilzomib.  Renal function must be monitored closely during tr eatment 
with carfilzomib.  Serum chemistry values, including creatinine, must be obtained and reviewed prior to each dose of carfilzomib on Day 1, 8, and 15 of all cycles .  Carfilzomib 
must be held for subjects with a CrCl < 15 mL/min at any time during st udy participation 
as outlined in Section 6.3
. 
• Subjects with active or suspected infection of any kind that required IV systemic 
treatment should not be dosed with carfilzomib until the infection has resolved and if being treated with anti -infective, the course of antibiotics has been completed.  
• Thrombocytopenia has been transient and typically resolves during the week between 
treatments.  For platelet counts ≤ 25,000/mm3, carfilzomib dosing must be held.  If  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
33 
 platelet counts do not recover, the dose of carfilzomib may be reduced or held according 
to the Dose Reductions / Adjustments rules outlined in Section 6.3 . 
• Subjects should have anemia treated  in accordance with the Institutional guidelines.  
• Carfilzomib treatment can cause nausea, vomiting, diarrhea, or constipation sometimes 
requiring the use of antiemetics or antidiarrheals.  Fluid and electrolyte replacement 
should be administered as clinically indicated to prevent dehydration.  
• Subjects with a history of HBV should be closely monitored for signs and symptoms of 
active HBV infection throughout treatment with carfilzomib, including the 30- day safety 
monitoring follow -up period. 
• Subjects receiving carfilzomib should be monitored for any new or worsening neurologic, cognitive or behavioral signs and symptoms that may be suggestive of Progressive 
Multifocal Leukoencephalopathy (PML) as part of the differential diagnosis of central 
nervous system disorders. If P ML is suspected, subjects should be referred to a specialist 
and appropriate diagnostic testing should be initiated. If a PML diagnosis is confirmed, 
carfilzomib should be permanently discontinued.  
• Contraception/Female: Females of childbearing potential sh ould be advised to avoid 
becoming pregnant while being treated with carfilzomib. Given that carfilzomib was clastogenic in the in vitro chromosomal aberration test in peripheral blood lymphocytes, as a precaution, females of childbearing potential and/or t heir male partners should use 
effective contraception methods or abstain from sexual activity during and for 30 days  
after treatment with carfilzomib. If pregnancy occurs during this time, patients  should be 
apprised of the potential hazard to the fetus.  
 Based on its mechanism of action and findings in animals, carfilzomib can cause fetal 
harm when administered to a pregnant woman. Carfilzomib caused embryo‐fetal toxicity in pregnant rabbits at doses that were lower than in subjects receiving the recommended dose. Carfilzomib administered to pregnant rats and rabbits during the period of organogenesis was not teratogenic at doses up to 2 mg/kg/day in rats or up to 0.8 
mg/kg/day in rabbits. If carfilzomib is used during pregnancy, or if the subject becomes 
pregnant while taking this drug, she should inform the investigator or study staff immediately. The investigator should notify Amgen of the pregnancy and discuss follow -
up with the subject. It is not known if carfilzomib will reduce the efficacy of  
oral contraceptives. Due to an increased risk of venous thrombosis associated with carfilzomib, subjects currently using oral contraceptives, or a hormonal method of contraception associated with a risk of thrombosis should consider an alternative method of effective contraception.  
 
• Breastfeeding: No studies of carfilzomib have been conducted in breastfeeding women. 
Carfilzomib  should not be used during breastfeeding. Breastfeeding women and women 
planning on breastfeeding may not participate in clinical tr ials with carfilzomib.  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
34 
 If a woman breastfeeds during the study, she must inform the investigator or study staff  
immediately. The investigator should notify Amgen that the subject has breastfed the  
infant and discuss follow‐up with the subject.  
 
• Contracepti on/Male:  Males of reproductive potential should be advised to avoid fathering 
a child while being treated with carfilzomib. The potential for carfilzomib to be 
transferred via semen and its effect on sperm are unknown. Male subjects  should refrain 
from donating sperm for at least 90 days after the last dose of carfilzomib. Male subjects 
treated with carfilzomib and/or their female partners (if of childbearing potential) should 
use effective contraceptive methods or abstain from sexual activity while treated  with 
carfilzomib and for 90 days  after treatment. If pregnancy occurs during this time, patients 
should be apprised of the potential hazard to the fetus. 
 
Male subjects should be advised to inform the investigator or study staff immediately in 
the event t hat their female partner becomes pregnant during the study. Upon receipt of 
this information, the investigator should notify Amgen of t he pregnancy and discuss 
follow -up regarding the pregnancy outcome with the subject. 
5.1.4 Carfi lzomib Drug Supply  
Vials of car filzomib contain 60 mg  of sterile white to off -white lyophilized cake or powder. The 
vial amount may exceed  the required dose;  however vials are for single use only.  Mixing 
carfilzomib with or administering as an infusion with other medicinal products is not allowed. 
Unopened vials will be stored in the original package  to protect from light exposure  at 2oC to 
8oC (36oF to 46oF). Carfilzomib will be supplied by Amgen. 
5.2 Dexamethasone Dosage and Administration  
Formulation:  Dexamethasone is available in seven potencies (0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, and 6 mg) in tablet form.  
Storage and Stability:   Dexamethasone is to be stored at room temperature.  
Administration:  For this study, dexamethasone is administered orally. Dexamethasone is adminis tered  prior to carfilzomib  at 40 mg on Days 1, 8, and 15 of  each  28 day cycle for all 
cycles . A 20 mg dose may be considered for subjects ≥ 75 years of age and for diabetic subjects. 
Supplier:   Dexamethasone will be commercially supplied.  Please refer to the package insert for 
complete information.  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
35 
 5.3 Ruxolitinib Dosage and Administration  
Ruxolitinib is administered orally with or without food at  the assigned cohort dose (5, 10 or 15 
mg) during Phase I  or the MTD  twice daily  continuously fo r 28 days  during Phase II  (see Section 
4.2.1  for dosing cohorts) .  If a dose is missed, the subject  should not take an additional dose, but 
should take the next usual prescribed dose.  
5.3.1 Safety Considerations  
• Treatment with ruxolitinib  can cause thrombocytopenia, anemia and neutropenia. 
Manage thrombocytopenia by reducing the dose or temporarily interrupti ng ruxolitinib. 
Platelet transfusions may be necessary.  Subjects developing anemia may require blood 
transfusions and/or dose modifications of ruxolitinib. Severe neutropenia (ANC less than 
0.5 X  109/L) was generally reversible by withholding ruxolitinib until recovery. Perform 
a pre- treatment complete blood count (CBC) and monitor CBCs every 2 to 4 weeks until 
counts are stabilized, and then as clinically indicated.  
• Serious bacterial, mycobacterial, fungal and viral infections have occurred. Delay starting  
therapy with ruxolitinib  until active serious infections have resolved. Observe subject 
receiving ruxolitinib for signs and symptoms of infection and manage promptly. 
• Tuberculosis infection has been reported in patients receiving ruxolitinib. Observe 
subjects receiving ruxolitinib for signs and symptoms of active tuberculosis and manage 
promptly. Prior to initiating ruxolitinib, subjects should be evaluated for tuberculosis risk factors, and those at higher risk should be tested for latent infection. For s ubjects with 
evidence of active or latent tuberculosis, consult a physician with expertise in the 
treatment of tuberculosis before starting ruxolitinib. The decision to continue ruxolitinib 
during treatment of active tuberculosis should be based on the ove rall risk -benefit 
determination.  
• Progressive multifocal leukoencephalopathy (PML) has occurred with ruxolitinib treatment. If PML is suspected, stop ruxolitinib and evaluate.  
• Advise subjects about early signs and symptoms of herpes zoster and to seek treat ment as 
early as possible if suspected.  
• Hepatitis B viral load (HBV -DNA titer) increases, with or without associated elevations 
in alanine aminotransferase and aspartate aminotransferase, have been reported in patients with chronic HBV infections taking ruxolitinib. The effect of ruxolitinib on viral replication in patients with chronic HBV infection is unknown. Subjects with chronic 
HBV infection should be treated and monitored according to clinical guidelines. 
• Non-melanoma skin cancers including basal cel l, squamous cell, and Merkel cell 
carcinoma have occurred in patients treated with ruxolitinib . Perform periodic skin 
examinations. 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
36 
 • Treatment with ruxolitinib has been associated with increases in lipid parameters 
including total cholesterol, low -density l ipoprotein (LDL) cholesterol, and triglycerides. 
The effect of these lipid parameter elevations on cardiovascular morbidity and mortality 
has not been determined in patients treated with ruxolitinib. Assess lipid parameters 
approximately 8- 12 weeks followi ng initiation of ruxolitinib therapy at investigator 
discretion . Monitor and treat according to clinical guidelines for the management of 
hyperlipidemia. 
5.3.2 Ruxolitinib Drug Supply  
Ruxolitinib 5 mg tablets are round and white to off -white in color.  
 
Ruxolitin ib will be supplied as 5 mg tablets packaged in 60- count high- density polyethylene 
bottles. All tablet excipients comply with the requirements of the applicable compendial 
monographs.  Ruxolitinib will be supplied by Incyte. All Incyte investigational prod uct labels will be in the 
local language and will comply with the legal requirements of each country and will state "Caution: New Drug--Limited by Federal (or United States) law to investigational use."  
Bottles of ruxolitinib tablets should be stored at ro om temperature, 15°C to 30°C (59°F to 86°F) . 
5.4 Treatment Compliance 
Subject compliance with the treatment and protocol includes ability and willingness to comply with all aspects of the protocol.  At the discretion of the Sponsor -Investigator, a subject may be 
discontinued from the protocol for non- compliance with follow -up visits or study drug.  
5.5 Duration of Therapy 
In the absence of treatment delays due to adverse event(s), treatment will continue until one of 
the following criteria applies : 
• Disease progression (after ruxolitinib is in itiated)  
• Intercurrent illness that prevents further administration of treatment  
• Unacceptable adverse event(s)  
• Subject decides to withdraw consent for treatment  
• General or specific changes in the subject’s condition render the subject unacceptable for 
further treatment in the judgment of the Investigator. 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
37 
 5.6 Drug Accountability  
Ruxolitinib and c arfilzomib  will be stored at the investigational site s in accordance with Good 
Clinical Practice (GCP) and Good Manufacturing Practice (GMP) requirements and will be 
inaccessible to unauthorized personnel .  
An adequate record of receipt, distribution, and destruction of all study drugs  must be kept in the 
form of a  drug accountabilit y log per investigational site, Amgen, and Incyte requirements.  The 
site Principal Investigator, or responsible party designated by the site Principal Investigator, will 
maintain a careful record of the inventory. Drug accountability logs will be subject to monitoring 
by the Sponsor . 
Study drug will be dispensed to subjects from the site investigational pharmacy. Unused drug will be returned to the investigational pharmacy from which it was dispensed.  Upon termination 
or completion of the study, all unuse d Amgen study drug should be returned  to Amgen and all 
unused Incyte study drug should be returned to Incyte. If Amgen and/or Incyte directs that study 
drug should be destroyed upon termination or completion of the study, appropriate documentation will be provided by the site investigational pharmacy.  
  
6 DOSE MODIFICATIONS  
6.1 Phase I  and P hase II Dose Modification and Dose Delay  
Dose reductions are not per mitted during Cycle 1 of Phase I unless the subject  experiences a 
DLT.  The subject  may continue  protocol therapy if the toxicity resolves,  and the subject  can be 
managed by a dose modification as detailed in this section.  However, the occurrence of the DLT 
will be counted toward the assessment of the MTD.  Dose reductions are permitted in subsequent 
cycles of Phase I and during all cycles of  Phase II for clinically significant hematologic and non-
hematologic toxicities.  Held doses are not made up. 
The prophylactic use of G-CSF and platelet transfusions in C ycle 1 of the dose escalation cohorts 
in Phase I  is not permitted.  Dose adjustments are permitted according to rules described in this 
section.  Dose modifications different from those stated in the protocol should only be made in 
consultation with the Sponsor -Investigator;  unless required for immediate subject  safety.   
Administration of the study drugs will be discontinued in the event of a treatment -related toxicity 
that persists despite appropriate dose reductions or any other toxicity that, in the opinion of the Investi gator, warrants discontinuation.   
Toxicity will be assessed using the CTCAE version 4.03 (Appendix 18.2
).   
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
38 
 All dose modifications should be based on the worst preceding toxicity  
6.2 Dose Reduction Steps  
6.2.1 Carfilzomib  Dose Reduction Steps  
Carfilzomib Dose Reduction Steps  
Starting Dose  Dose reduction 
step - 1 Dose reduction 
step - 2 Dose reduction  
step - 3 
56 mg/m2 45 mg/m2   36 mg/m2  27 mg/m2  
 
6.2.2 Dexamethasone Dose Reduction Steps  
If a subject  is unable to tolerate dexamethasone due to dexamethasone related toxicity  despite 
dose reduction to 12 mg, dexamethasone may be discontinued.  However, the subject may  
continue on study treatment after discussing with the Sponsor -Investigator .   
Dexamethasone Dose Reduction Steps  
Starting Dose  Dose reduction step - 1 Dose reduction step - 2 
40 mg  20 mg  12 mg  
 
6.2.3 Ruxoli tinib Dose Reduction Steps  
Ruxolitinib Dose Reduction Steps  
Starting Dose  Dose reduction step - 1 Dose reduction step -2 
15 mg bid 10 mg  bid 5 mg bid 
10 mg bid   5 mg bid 5 mg qd (consider)  
  5 mg bid    5 mg qd (consider)  - 
 
6.3 Dose Modification Guidelines  for Carfilzomib and Ruxolitinib  during a Cycle of 
Therapy  
Hematologic  Toxicity  Recommended  Action  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
39 
 • Grad e 3a or 4 Neutropenia   
(ANC < 1000 mm3)  
• Grad e 4 Thrombocytopenia  
(Platelets < 25,000 mm3)  or any grade 
with bleeding.  
 • Withhold  ruxolitinib and carfilzomib  and re- evaluate in one week  
• If recovered  to Grade 1  or better before  next scheduled  dose,  
continue  ruxolitinib and carfilzomib at  same dose  level.  
• If recovered  to Grade  2 neutropenia  or Grade  3 
thrombocytopenia,  reduce  ruxolitinib  and carfilzomib dose by one 
dose level . 
Reductions in one drug and not the other may be considered with 
alternating dose reductions for subsequent occurrence.   
 
• If tolerated,  the reduced  dose may be escalated  to the previous  
dose at the discretion  of the physician.  
Non-Hematologic  Toxicity  Recommended  Action  
Cardiac  Toxicity  
Grad e 3 or 4, new onset or worsening of: 
• congestive  heart  failure;  
• decreased  left ventricular  functio n; 
• or myocardial  ischemia  • Withhold  carfilzomib until resolved or returned  to baselin e. 
• After  resolution,  consider  restarting  carfilzomib  at a reduced 
next dose level  if appropriate .  
• If tolerated,  the reduced  dose may be escalated  to the previous 
dose at the discretion  of the physician.  
Pulmonary  Hypertension  
 • Withhold  carfilzomib until resolved or returned  to baseline.  
• Restart  at the  dose used prior  to the event  or next dose level  at the  
discretion  of the physicia n. 
• If tolerated,  the reduced  dose may be escalated  to the previous 
dose at the discretion  of the physician.  
Pulmonary  Complications  
• Grad e 3 or 4 
 • For drug related Grade 3 or 4 pulmonary toxicity, permanently 
discontinue  carfilzomib . 
 
Hepatic  Toxicity  
• Grade  3 or 4 elevation  of 
transaminases,  bilirubin  or other  liver 
abnormalities  
 • Withhold  carfilzomib and ruxolitinib until resolved  or returned  to 
baselin e. 
• After  resolution,  consider  if restarting  carfilzomib  and ruxolitinib  is 
appropriate; may  be reinitiated  at a reduced  dose with frequent  
monitoring  of liver 
functio n. 
• 25% dose reduction of carfilzomib  in case of baseline or treatment 
emergent mild or moderate hepatic impairment . 
• Restart  ruxolitinib  with one dose level  reduction.  
• If tolerated,  the reduced  doses of both drugs  may be escalated  
to the previous dose s at the discretion  of the physician.  
 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
40 
 Renal  Toxicity  
• Serum  creatinine  equal  to or greater 
than 2 × basel ine 
 • Withhold  carfilzomib  and ruxolitinib  until renal  function has 
recovered  to Grade 1 or to baseline  and monitor  renal  
functio n. 
• Carfilzomib must be held for subjects with a CrCl < 15 
mL/min at any time during study participation . 
• If attributable  to carfilzom ib, restart  at the  next scheduled 
treatment  at a reduced  dose  
• If not attributable  to carfilzomib , restart  at the dose used prior  
to the  event . If attributable to ruxolitinib, restart with one 
dose level reduction.  
• If not attributable to ruxolitinib, restart at the dose used prior to 
the event  
• If tolerated,  the reduced  dose may be escalated  to the previous 
dose at the discretion  of the physicia n. 
Posterior Reversible Encephalopathy Syndrome (PRES)  • If PRES is suspected, hold carfilzomib. Consider evaluation 
with MRI for onset of symptoms suggestive of PRES.  
• If PRES is confirmed, permanently discontinue carfilzomib.  
• If PRES is excluded, may resume carfilzomib at same dose 
if clinically appropriate . 
• If PRES recurs, permanently discontinue carfilzomib.  
Thrombotic Microangiopathy (TMA)  • If TMA is suspected, hold carfilzomib and manage per 
standard of c are. 
• If TMS is confirmed and related to carfilzomib, permanently 
discontinue carfilzomib.  
• If TMA is excluded, may restart carfilzomib.  
If Progressive Multifocal Leukoencephalopathy (PML) is 
suspected  • Hold carfilzomib  
• Refer to a specialist; appropriate diagnostic testing should 
be initiated  
• If a diagnosis of PML is confirmed, permanently 
discontinue carfilzomib  
Active HBV reactivation  • Withhold carfilzomib until the infection is adequately controlled. If the benefits outweigh the risks, carfilzomib 
may be resumed with concomitant prophylaxis as per local 
standard of care. Consult a liver disease specialist as clinically indicated.  
Active or suspected infection of any kind that requires systemic treatment  • Hold carfilzomib until the infection has resolved and the 
course of antibiotics has been completed, if being treated 
with an anti- infective(s)  
Other Grade 3 or 4 non -hematologic 
toxicity  • Evaluate attribution and withhold the appropriate therapy.  
If resolved to ≤ Grade 1 or baseline, restart the withheld 
therapy with one level dose reduction of suspected drug.  
• If tolerated,  the reduced dose may be escalated to the 
previous dose  at the discretion  of the physicia n. 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
41 
 a National Cancer Institute Common Terminology Criteria for Advers e Events (NCI CTCAE) Version 
4.03 
6.4 Dose Modification Guidelines for Dexamethasone 
Dose M odifications for Toxicity R elated to D examethasone  
Body System  Symptom  Recommended Action  
Gastrointestinal  Dyspepsia, gastric or duodenal  
ulcer, gastritis Grade 1 –2  
(requiring medical management)  Treat with H2 blockers, sucralfate, 
or omeprazole. If symptoms persist 
despite above measures, decrease 
dexamethasone dose by 1 dose level.  
Gastrointestinal  > Grade 3  
(requiring hospitalization or surgery)  Hold dexamethasone until symptoms 
adequately controlled. Restart and decrease one dose level of current dose along with concurrent therapy with H2 blockers, sucralfate, or omeprazole. If symptoms persist despite above measures, discontinue 
dexamethasone and do not resume.  
Gastrointestinal  Acute pancreatitis  Discontinue dexamethasone and do 
not resume  
Cardiovascular  Edema  
> Grade 3 (limiting function and 
unresponsive to therapy or anasarca)  Diuretics as needed, and decrease 
dexamethasone dose by 1 dose level; if edema persists despite above measures, decrease dose another dose level. Discontinue dexamethasone and do not resume if symptoms pers ist despite second 
reduction.  
Neurology  Confusion or Mood alteration  
> Grade 2 (interfering with 
function +/ - interfering with 
activities of daily living)  Hold dexamethasone until symptoms 
resolve. Restart with one dose level reduction. If symptoms persist despite above measures, discontinue 
dexamethasone and do not resume.  
Musculoskeletal  Muscle weakness  
> Grade 2 (symptomatic and 
interfering with functio n +/- 
interfering with activities of daily living)  Decrease dexamethasone dose by 
one dose level. If weakness persists despite above measures, decrease dose by one dose level. Discontinue dexamethasone and do not resume if 
symptoms persist.  
Metabolic  Hype rglycemia  > Grade 3 or 
higher  Treatment with insulin or oral 
hypoglycemics as needed. If 
uncontrolled despite above 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
42 
 measures, decrease dose by one dose 
level until levels are satisfactory.  
 
6.5 Criteria for Initiation of a New Cycle of Therapy  
For a new cycle of treatment to begin, the subject must meet the following criteria:  
• ANC must be ≥ 1,000/mm3. 
• Platelet count must be greater than or equal to 25,000/mm3  
• All other non- hematologic treatment -related toxicity (except for alopecia) must have 
resolved to ≤ Grade 1 or to the subject ’s baseline condition, with the exception of fatigue 
which must have resolved to ≤  Grade 2 . 
If the subject fails to meet the above -cited criteria for initiation of the next cycle of treatment, 
dosing should be delayed f or 1 week. At the end of that time, the subject should be re -evaluated 
to determine whether the criteria have been met. If the subject continues to fail to meet the 
above -cited criteria, delay  therapy and continue to re -evaluate. The maximum delay before 
treatment should be discontinued will be 3 weeks  or at the discretion of the Investigator. Phase 
II/Run- In only: beginning with Cycle 1, disease evaluation results should be available prior to 
dosing on Day 1 of each cycle  until initiation of ruxolitinib  (Phase II/Ruxolitinib) . 
7 CONCOMITANT MEDICATIONS  
All baseline medications that the subject  is taking within 14 days prior to the initiation of therapy 
must be recorded  in the subject medical record .  All additional medications (other than study 
drug or changes in baseline medications) administered during the study must be listed in the subject’s medical record . 
All medication that is considered necessary for the subject’s welfare, and which is not e xpected 
to interfere with the evaluation of the study treatment, may be given at the discretion of the Investigator.  
7.1 Required Concomitant Therapy  
• Female subjects of child -bearing potential must agree to use dual methods of 
contraception for the duration of the study and for 30 days  following the last dose of 
study treatment .  Male subjects must agree to use a barrier method of contraception for 
the duration of the study and for 90 days  following the last  dose of  study treatment  if 
sexually active with a fe male of child -bearing potential. 
• In addition, subjects must receive acyclovir or similar ( famciclovir , valacyclovir) anti -
varicella (anti -herpes) agent prophylaxis. All subjects must receive prophylaxis with 
hydration as per Section 5.1.2.1. 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
43 
 • Thromboprophyl axis is recommended for subjects  being treated with the combination of  
carfilzomib with dexamethasone. The thromboprophylaxis regimen should be based on 
an assessment of the subject’s underlying risks.  
7.2 Recommended /Allowed  Concomitant Therapy  
• Prophylactic t reatment with anti- emetic(s) prior to carfilzomib administration is 
recommended. Subsequent anti -emetic drugs against delayed emesis will be administered 
at the discretion of the investigator.  
• Full supportive care  is recommended , including transfusions of  blood and blood products 
(including platelets), antibiotics, anti -diarrheals, analgesics, etc. and prophylactic 
treatment for tumor lysis syndrome when appropriate.  
• Bisphosphonate therapy IV or PO is recommended to be administered if indicated in 
accordance with institutional guidelines.  
• Prophylaxis with antivirals should be  given to all  subjects  unless contraindicated, 
especially subjects  who are carriers of HBV.  
• The prophylactic use of G-CSF and platelet transfusions  is permitted except  in C ycle 1 of 
the dose escalation cohorts  (Phase I) unless the subject has hematologic DLT . 
Erythropoi esis-stimulating agents  are permitted  throughout the duration of study 
treatment  (any cycle) . 
• Palliative radiation is allow ed  
7.3 Contraindicated Concomitant Therapy  
• Strong CYP3A4 inhibitors (such as but not limited to boceprevir, clarithromycin, conivaptan, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, 
mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, 
telithromycin, voriconazole) and fluconazole are not permitted in combination with 
ruxol itinib.  
• Concurrent therapy with any approved or investigative anticancer therapeutic drug with activity against multiple myeloma is not allowed.  
• Corticosteroids for non- malignant conditions (e.g., asthma, inflammatory bowel disease) 
> prednisone 10 mg/day (or its equivalent) are not permitted.   
• Other investigative agents  for multiple myeloma  or any other indication should not be 
used during the study. 
8 STUDY PROCEDURES  
Please see Table of Events ( Appendix 18.5
) for d etails regarding t he timing and description of all 
study procedures.  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
44 
 8.1 Registration  
Potentially eligible and interested subjects will be presented with the study informed 
consent. Following informed consent, subjects will be registered by the Coordinating 
Center and assigned a four digit number S equence Number , where 1001 will be the 
Sequence N umber assigned to the first registered subject.  
No protocol -related assessments may be performed prior to obtaining informed consent.  Men 
and women of child bearing potential on study will be counseled regarding the need to use contraception throughout the course of the study and for  30 days  (female subjects) or  90 days  
(male subjects)  after the last dose of study treatment.  
8.2 Informed Consent  
The subject must read, understand, and sign the Institutional Review Board/Research Ethics Board/Independent Ethics Committee (IRB/REB/IEC) approved informed consent form (ICF) 
confirming his or her willingness to participate in this study before any study- specific screening 
procedures are performed. Subjects must also grant permission to use protected health information per the Health Insurance Portability and Accountability Act (HIPAA). In addition, 
subjects must sign all applicable IRB - approved ICF amendments per the site IRB/REB/IEC 
guidelines during the course of the study.  
8.3 Screening Procedures  
All screening  procedures must  be completed within 21 days prior to start of study treatment 
unless otherwise spe cified in the Table of Events  (Appendix 18.5
) 
• Informed consent  
• Inclusion/exclusion 
• Medical and disease history  
• Physical examination  
• Vital signs  
• ECOG performance status  
• Pregnancy test for females of child bearing potential  
• Electrocardiogram (ECG)  
• ECHO, MUGA, or cardiac MRI  
• Concomitant medications  - all on -going medic ations and those taken within 14 days prior 
to first dose  of study treatment  
• Disease Assessments (see section 8.4.1)  
• Laboratory Assessments (see section 8.4.2)  
 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
45 
 8.3.1 Disease assessments: Baseline measurements  
• Bone marrow aspirate and serum for disease assessment and correlative studies: for %  
plasma cells, morphology, standard karyotype, cytogenetics by FISH and biomarkers  
• Correlative bone marrow specimen: minimum of  12 mL  of bone marrow aspirate will be 
collected and sent to the LCI HOT lab . 
• Response assessments, including serum or urine protein electrophoresis (SPEP/UPEP), 
serum and Urine immunofixation (IFE), serum free light chains (SFLC) /ratio  
• β2 microglobulin 
• Radiologic imaging of plasmacytoma as clinically indicated (same technique to be used throughout the trial).  Positron emission  tomography/computed tomography (PET/CT) 
scan or magnetic resonance imaging (MRI) as clinically indicated  
• Bone skeletal surve y  
 
Please note that for subjects  in Phase II/Run- In who cross over to Phase II/Ruxolitinib, a new 
baseline should be established f or disease assessments prior to initiating ruxolitinib.  Response to 
treatment with ruxolitinib will be calculated using this new baseline.  
8.3.2 Screening Laboratory assessments:  
• Hematology -  hemoglobin, WBC with differential, and platelet count  
• Coagulation -  PT/INR  
• Blood chemistries -  sodium, chloride, potassium, magnesium, phosphate, uric acid, BUN, 
glucose (fasting at baseline), ALT/AST (SGPT/SGOT), alkaline phosphatase, total 
protein, total bilirubin, albumin, serum creatinine and estimated cr eatinine clearance (see 
Appendix 18.4), calcium and lactate dehydrogenase (LDH).  Viral hepatitis panel including HBsAg, HB core antibody, HB surface antibody, HepC antibody and HIV at 
baseline only. 
o HBV DNA testing (by PCR):  only for subjects positive for Anti -HBc or Anti -
HBs  
• Disease specific laboratory evaluations as noted above. 
• Correlative blood specimen  
 
8.4 On Study Procedures:  
• Vital signs  
• Physical Exam  
• Laboratory assessments  
• ECOG performance statu s 
• Concomitant medications and procedures  
• Adverse event mo nitoring 
• ECHO, MUGA, or cardiac MRI  
• Correlative  studies (Blood and bone marrow  aspirate)  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
46 
 o Note: Po st-baseline correlat ive samples  should only be collected on subjects 
receiving ruxolitinib (Phase I and Phase II/Ruxolitinib). 
8.4.1 Disease assessments:  
• Response assessments, including serum or urine protein electrophoresis (SPEP/UPEP), 
serum and Urine immunofixation (IFE), serum free light chains (SFLC) /ratio  
o The following assessments will be performed at each urine disease evaluation:  
 Total protein  
 UPEP  
 Urine immunofixation electrophoresis (UIFE)  
o For subjects whose disease is not measurable by UPEP at Baseline, a 24 -hour urine 
sample for UPEP and Urine immunofixation (UIFE) will be collected every 3 
cycles at a minimum.  
• If disease has not progressed and new anti -cancer treatment has not been start ed after  study 
treatment discontinuation, response assessment samples should also be collected per 
standard of care  during the follow -up visits. 
• Radiologic imaging of plasmacytoma as clinically indicated (same technique to be used throughout the trial).  Positron emission tomography/computed tomography (PET/CT) 
scan or magnetic resonance imaging (MRI) as clinically indicated  
• Bone skeletal surve y as clinically indicated and to confirm progression if needed.  
• Phase II /Run- In only: Beginning with Cycle 1, disease evaluation  results  to assess response 
should be available for investigator review prior to dosing on Day 1 (up to 7 days prior)  of 
each cycle until initiation of ruxolitinib . Cycle numbers start over  with the initiation of 
ruxolitinib  (the first cycle of ruxolitinib will be Cycle 1)  and a new disease response 
baseline will be established  (Phase II/Run -in subjects who cross over to Phase 
II/Ruxolitinib) . 
 
8.4.2 Laboratory assessments:  
• Hematology -  hemoglobin, WBC with differential, and platelet count  
• Blood chemistries -  sodium, chloride, potassium, magnesium, phosphate, uric acid, BUN, 
glucose (fasting at baseline), ALT/AST (SGPT/SGOT), alkaline phosphatase, t otal protein, 
total bilirubin, albumin, serum creatinine and estimated creatinine clearance, calcium and 
lactate dehydrogenase (LDH).   
• Brain Natriuretic Peptide  (BNP)  
• Disease specific laboratory evaluations as noted above. 
• Correlative studies ( blood and bone marrow) . Note: ruxolitinib must have been initiated 
in order to collect correlatives  post -baseline.  
8.5 End of Treatment  
The end of treatment (EOT) visit is done when the subject  discontinues study treatment  for any 
reason. The decision to discontinue study treatment due to progression must be based on the 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
47 
 evaluation of lab assessment. If the decision to permanently discontinue the study treatment is 
made during a scheduled visit, then the EOT visit should be performed instead of the scheduled visit. If the decision is made between scheduled visits, an EOT visit should be performed no later 
than 30 days after the last treatment administration or prior to the start of new subsequent anti -
cancer therapy, whichever occurs first. 
8.6 Follow -Up 
Subjects  who received ruxolitinib on study and discontinue therapy for reasons other than 
disease progression should continue to have standard of care  disease assessments done until 
progression or start of subsequent therapy.  At such time, follow -up or overall survival status will 
take place ev ery three months +/ - 7 days until death, lost to follow up, or until the criteria defined 
for the final analyses (Section 13.4.1) are reached.  However, in the event the criteria for the final 
analysis are met, and there are subjects who have not yet been discontinued from study 
treatment, subjects in follow up will continue to be followed until all subjects have discontinued study treatment and completed the required 30 day safety monitoring period (Section 9.3) .  
Follow -up beyond the safety monitoring per iod is only required for subjects who received 
ruxolitinib . 
8.7 Off-Study  
Subjects will remain on study until the criteria for the final analysis have been met. Reasons a 
subject may be removed from the study early include, but are not limited to:  
• Subject non- compliance with study participation, in the opinion of the investigator  
• The subject or legal representative (such as a parent or legal guardian) withdraws study 
consent  
• The subject is lost to follow -up 
• Investigator’s decision to withdraw the subject  
• Subjec t death  
• Early study termination  
 
Subjects who do not receive ruxolitinib will be taken off study after completion of the safety 
monitoring period (Section 9.3)  
When subjects are removed from the study, the reason for study removal and date the subject was removed should be documented.  
Subjects that are Off Study will not participate in any study related procedures, including data 
collection.  The study will be considered complete when one or more of the following conditions 
is met:  
• All subjects have completed all study visits.  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
48 
 • All subjects have discontinued from the study.  
• The IRB, LCI DSMC, Sponsor -Investigator or Amgen  or Incyte  discontinues the study 
because of safety considerations.  
• The Sponsor -Investigator defines an administrative or clinical cut- off date.  
8.7.1 Subject Withdrawal  
In all cases, the reason for withdrawal must be recorded in the subject’s medical record  and/or 
resea rch chart  and CTMS . 
8.7.2 Screen Failures  
A subject who, for any reason (e.g. failure to satisfy the selection criteria or withdraws consent), 
terminates the study before receiving first dose of the study regimen  (Cycle 1, Day 1) is regarded 
as a “screen failure ”.   
9 ADVERSE EVENTS  
9.1 Adverse Event  
An adverse event (AE) is any symptom, sign, illness or experience that develops or worsens in 
severity during the course of the study.  Intercurrent illnesses or injuries should be regarded as 
AEs.  Abnormal results of dia gnostic procedures are considered to be AEs if the abnormality:  
• results in study withdrawal  
• is associated with a serious AE  
• is associated with clinical signs or symptoms  
• leads to additional treatment or to further diagnostic tests  
• is considered by the Investigator to be of clinical significance  
9.2 Serious Adverse Event (SAE):  
An event is “serious” if it involves considerable detriment or harm to one or more persons (who may or may not be participants ) or required intervention to prevent one or more persons fr om 
experiencing considerable detriment or harm. SAEs include:  
• Death  
• Life-threatening experience – Disease or condition where the likelihood of death is high 
unless the course of the disease/condition is interrupted or diseases/conditions with potentially f atal outcomes where the end point of the clinical trial analysis is survival 
• Inpatient hospitalization or prolongation of hospitalization 
• Persistent or significant disability/incapacity  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
49 
 • Congenital anomaly/birth defect in subject ’s offspring  
• Any other important medical event that, based upon appropriate medical judgment, may 
jeopardize the participant,  and may require medical or surgical intervention to prevent 
one of the outcomes listed above.  Examples include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions 
that do not result in inpatient hospitalization, the development of drug dependency or 
drug abuse, suicidal ideation or attempts, or the unintentional revealing of some genetic 
information to insurers.  
9.2.1 Related:  
An event is “related” if , in the opinion of the Investigator, it was definitely or possibly was 
caused by the research activity.  
9.2.2 Unexpected:  
An event is “unexpected” when its specificity, nature, severity or incidence is not accurately 
reflected in the investigator’s brochure or Package Insert previously reviewed and approved by 
the IRB.  Examples include a lower rate of response to treatment or a side effect that is more 
severe than initially expected.   
9.3 Overlappin g Toxicities  
There is a possibility that hematologic toxicities and non -hematologic toxicities may overlap 
during study treatment. Overlapping toxicities will be monitored closely in both the Phase I and 
Phase II portions of the study. 
9.4 Adverse Event Report ing 
All Adverse Events (AE) will be recorded by the Investigator from the time of the start of study 
treatment through the end of the designated safety monitoring follow -up period (30 days after 
last dose  of study treatment ).  AEs and study treatment administration must be recorded in the 
eCRF  within 5 business days of awareness. All relevant historical medical conditions that are 
known/diagnosed prior to the administration of study drug(s)  and ongoing at the time of study 
treatment  initiation  are to be recorded.  
9.5 Abnormal Laboratory Values Defined as AEs  
An abnormal laboratory value is considered to be an AE if  the laboratory abnormality is 
characterized by any of the following:  
• Results in discontinuation from the study 
• Requires treatment, modification of study drug dose, or any other therapeutic intervention 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
50 
 • Is judged by the Investigator to be of significant clinical impact/importance  
• Meets the criteria for a DLT as defined in Section 4.2.1.3 
If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis 
or syndrome should be recorded as an AE.  If the laboratory abnormality was not a part of a 
diagnosis or syndrome, then the abnormality should be recorded as the AE.  
9.6 Adverse Event Grading  
CTCAE term ( AE description) and grade: The descriptions and grading scales found in the 
revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 will be 
utilized for AE reporting.   
Grade refers to the severity (intensity) of the AE:  
 
CTCAEv4 .03 Grade 1 : mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention is not indicated. CTCAEv4 .03 Grade 2 : moderate; minimal, local, or noninvasive intervention is indicated; 
limiting to age -appropriate instrument al activities of daily living (ADL; instrumental ADL refers 
to preparing meals, shopping for groceries or clothes, using the telephone, managing money, 
etc.).  
CTCAEv4 .03 Grade 3 : severe or medically significant but not immediately life threatening; 
hospita lization or prolongation of hospitalization is indicated; disabling; limiting to self -care 
ADL (self -care ADL refers to bathing, dressing and undressing, feeding self, using the toilet, 
taking medications, and not bedridden).  
CTCAEv4 .03 Grade 4 : life-threatening consequences; urgent intervention is indicated. 
CTCAEv4 .03 Grade 5 : death due to an AE  
9.7 Adverse Event Attribution  
The Investigator will assess the relationship of the event to the study treatment . An adverse event 
is considered to be associated with the use of the study regimen if the attribution is determined as 
possible, probable or definite.  The relationship asses sment of the adverse event by the 
Investigator should be documented as follows:  
• Unrelated: The AE is clearly NOT related to the treatment.  
• Unlikely Related: The AE is doubtfully related to the treatment.  
• Possibly Related: The AE may be related to the treat ment.  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
51 
 • Probably Related: The AE is likely related to the treatment  
• Definitely Related: The AE is clearly related to the treatment.  
9.8 Communication b etween Investigational Sites  
Investigational sites will be required to report AEs for all grades an d attributio ns, SAEs, study 
drug administration, or any other problem that could affect the validity/integrity of the study data 
to the Sponsor -Investigator .  Study drug administration issues or any other problem  potentially 
affecting the validity/integrity of the stu dy data  should be communicated to the Sponsor by email 
or phone as soon as possible but within 2 business days of the Investigator learning of the event.  
10 SAFETY DATA COLLECTION, RECORDING AND REPORTING  
Safety variables include the following: AEs and SAEs (whether related to study treatment  or 
not), laboratory changes , changes in vital signs and, in some instances, changes in images, as 
evaluated  at the Investigator ’s discretion.  A dverse events will be e valuated continuously 
throughout the study. Safety and tolerability, relationship to treatment and intensity will be 
assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) vers ion 
4.03.  All adverse events (Grades 1 – 5) will be d etermined by the Investigator  and documented 
in subject study charts .  
It is the responsibility of the Sponsor -Investigator, Investigators and the Protocol Team to ensure 
SAEs are reported according to the Code of Federal Regulations, Good Clinical Practic es, the 
protocol guidelines, Institutional Review Board, and FDA policy.  
10.1 SAE /Pregnancy and Lactation  Reporting to Sponsor -Investigator  
Upon learning of an event, Investigators/Investigational Sites must notify the Sponsor -
Investigator of any SAE and pregnancy/lactation exposure within 1 business day of awareness 
from study treatment initiation through 30 days from the last dose of study treatment.  All SAEs 
must be followed to resolution or to stabilization if improvement or resolution is not expe cted.  
SAEs that are determined to be related to study treatment or protocol -mandated procedures are 
reportable for the duration of the subject’s participation in the trial. Each investigational site will 
be responsible to report SAEs that occur at their i nstitution to their respective IRB in accordance 
with the IRB reporting policy. 
When new significant information becomes available, a follow -up report must be reported to the 
Sponsor -Investigator within 1 business day of awareness.  
10.2 SAE  Reporting to the FDA  
The Sponsor -Investigator will be responsible for all communications with the FDA. Upon 
learning of the event, the Sponsor -Investigator will report to the FDA, regardless of the site of 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
52 
 occurrence, any serious adverse event (SAE) that meets the FDA’s criteria for expedited 
reporting following the reporting requirements and timelines in accordance with federal 
regulations.  
Unexpected fatal or life- threatening experiences associated with the use of an investigational 
product will be reported to the FDA as soon as possible but in no event later than 7 calendar days 
after initial receipt of the information.  All other serious , unexpected experiences associated with 
the use of the investigational product will be reported to the FDA as soon a s possible but in no 
event later than 15 calendar days after initial receipt of the information. 
 
The Sponsor -Investigator will notify any participating sites of SAEs reported to the FDA.  
10.3  SAE Reporting by Sponsor -Investigator to Amgen  and Incyte  
The Spons or-Investigator must notify Amgen regarding all SAEs occurring with carfilzomib.  
Subsequently, the Sponsor -Investigator  must notify Incyte regarding all SAEs occurring with 
ruxolitinib. T he MedWatch Form  FDA 3500A must be completed for each event and the form 
must be sent to the respective funding company based on the contact information and reporting 
timelines listed below.  
Note: Investigational sites are not responsible for submitting SAEs to funding companies as 
this is a sponsor responsibility.  
The Sponsor -Investigator  shall be responsible for collecting all SAEs and Pregnancy and 
Lactation Exposure Reports  from all investigational sites  and will exercise reasonable due 
diligence to obtain follow -up information from all investigational sites on incomplete SAE or 
Pregnancy and Lactation Exposure Reports.  In the event that the funding company requires 
clarification or further information on individual SAE or Pregnancy and Lactation Exposure Reports, the funding company will not cont act non -party investigators directly, but will route all 
such inquiries through Sponsor -Investigator for forwarding to such investigator(s). LCI  will be 
responsible to ensure such inquiries are completed and provided to Amgen and Incyte  in a timely 
manner .  
Information not available at the time of the initial report (e.g., an end date for the SAE, discharge 
summaries, lot numbers, relevant laboratory values, scan data and autopsy reports) which are 
received after the initial report must be documented on a f ollow -up MedWatch and submitted to 
Amgen  and Incyte.  The Sponsor -Investigator will be responsible for obtaining follow -up 
information for the SAEs and demonstrate diligence in attempting to obtain such information 
from investigational sites by, among othe r things, maintaining written records of such attempts.  
The Sponsor -Investigator  will provide an annual IND report to Amgen  and Incyte . Other reports 
containing safety data generated during the course of the study will be submitted to Amgen  and 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
53 
 Incyte at the time the Sponsor -Investigator submits to anybody governing research conduct ( i.e. 
regulatory authorities and IRBs ).  The Sponsor -Investigator  will su pport reconciliation of all 
SAE s at the end of the study at a minimum.  
10.3.1 Pregnancy Reporting  to Amgen an d Incyte   
Sponsor -Investigator will r eport Pregnancy and potential infant exposure including Lactation to 
Amgen and Incyte within the timeframes listed below: 
• Incyte: within 24 hours of Sponsor -Investigator awareness  
• Amgen : within ten (10) calendar days of  Sponsor -Investigator  awareness.  
10.3.2 Amgen  Reporting/ Contact Information  
All Serious Adverse Events (SAEs) occurring with carfilzomib required to be reported pursuant 
to section 10.3 of the protocol shall be provided to Amgen and its representatives by LCI or the 
Sponsor -Investigator on a MedWatch Form FDA 3500A according to the timelines below. 
• Expedited/SUSAR reports: Provide to Amgen within 24 hours  after submission to  the 
FDA . 
Copies of safety reports submitted to the FDA by the Sponsor -Investigator will be shared with 
the contact below so that these reports can be evaluated and included in investigator brochure or Amgen IND safety submissions as required to ensure safety of other subjects who are receiving 
the product from Amgen for sponsored trials.  Additionally, the Sponsor  will provide any 
additional reports agreed upon by LCI or the Sponsor -Investigator and Amgen which will 
include a line listing of all SAEs sent to Amgen every 6- 12 months . 
Amgen  Drug Safety and Pharmacovigilance Contact Information:  
Amgen Global Safety  
Toll-free #: 1 -888-814-8653 
Email (Only for sponsors with a secure email connection with Amgen) : svc-ags-us@amgen.com  
10.3.3 Incyte Reporting /Contact  Information  
All Serious Adverse Events (SAEs) occurring with ruxolitinib required to be reported pursuant to section 10.3 of the protocol shall be provided to Incyte and its representatives by LCI or the 
Sponsor -Investigator on a MedWatch Form FDA 3500A within 24 hour s of the Sponsor -
Investigator becoming aware of the event.  Copies of IND safety reports submitted to the FDA by 
LCI will be shared with the contact below so that these reports can be evaluated and included in 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
54 
 investigator brochure or Incyte IND safety subm issions as required to ensure safety of other 
subjects who are receiving the product from Incyte for sponsored trials.  
Incyte Corporation:   SafetyReporting@incyte.com  for e -mail transmission of individual S AE 
reports;  
Safety Contacts:      Kathy Lenard Roberts, VP, Global PhV Ops & Systems Quality Management  
                                                                Phone: 302- 498-6727  
                                                                Fax:      302- 425-2780  
                                                                 
Robert Livingston, MD, VP, Incyte PhV & Drug Safety 
                                                                Phone: 302- 498-7098  
                                                                Fax:     302- 425-2780  
10.4 Safety Reporting to the IRB  
All events occurring during the conduct of a protocol and mee ting the definition of an SAE will 
be reported to the  central  IRB per IRB requirements .   
Protocol deviations will be reported promptly to the  central  IRB per IRB requirements.     
11 DATA AND SAFETY MONITORING PLAN 
Data will be collected in electronic case report forms (eCRFs). Study personnel will be trained 
on data entry by the sponsor and provi ded protocol -specific eCRF guidelines.  
This protocol will be monitored according to the processes in effect for all Levine Cancer 
Institute Investigator - Initiated Trials  and will abide by applicable regulations and guidelines 
(e.g. Good Clinical Practice [GCP]) .  It is the responsibility of the Sponsor -Investigator to 
monitor the safety data for this study.  For the Phase I portion of the study, the Sponsor -
Investigator, Statistician , and other study team members, as applicable, will conduct a 
teleconference after  accrual of each cohort to review  safety data before approving opening of 
subsequent cohort s for accrual.  The Sponsor -Investigator,  and other  sponsor -level  study team 
members,  will meet to regularly to monitor  subject consents, enrollment and r etention, safety 
data and timeliness/validity/integrity of the data on a recurring basis .  Documentation of 
recurring meetings will be kept in the study files. The Sponsor -Investigator will submit reports to 
the LCI Data and Safety Monitoring Committee acc ording to the institutional LCI Data and 
Safety Monitoring Plan.  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
55 
 12 MEASUREMENT OF EFFECT 
12.1 Timing of Response Evaluation  
Response will be evaluated according to the s chedule of e valuations listed  on the Table of Events  
(Appendix 18.5 )  
12.2 Response Criteria:  
The IMWG Response Criteria will be used for all evaluations of response. ( Appendix 18.3 ) 
12.3 Measurable Disease:   
All subjects  must have baseline assessment of disease that meet the criteria of measurable 
disease defined below:  
• Serum M protein ≥ 0.5 g/dL (≥ 5 g/L)  for IgG, IgA, or IgM disease , quantified by using 
densitometry on serum protein electrophoresis (SPEP).  
AND / OR  
• Urine M protein [Bence- Jones Prote in] ≥ 200 mg/24 hrs (> 0.2 g/24 hrs), quantified by 
24-hour urine protein electrophoresis (UPEP see Appendix III: Notes, h.).  
OR 
• Subjects  who have both serum M protein levels < 0.5 g/dL AND urine M protein levels < 
200 mg/24 hrs at baseline may be followe d by serum free light chain (FLC) assay if 
involved free light chain level ≥ 10 mg/dL (≥ 100mg/L).  
13 STATISTICAL CONSIDERATIONS  
13.1 Sample Size  
13.1.1 Phase I  
Phase I up to 18 subjects  may be required to evaluate 3 dose levels of ruxolitinib  in combination 
with c arfilzomib and dexam ethasone in a standard  3 + 3 design.   
13.1.2 Phase II 
Progression- free survival at 4 months is the primary endpoint  for this study.  The current study is 
investigating the impact of adding ruxolit inib to the combination of  carfilzomib and 
dexamethasone in a carfilzomib refractory population.  Published study results on carfilzomib 
plus dexamethasone in a carfilzomib refractory population (as defined in this protocol) have not 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
56 
 been identified.  However, it is reported that the time on treatment in multiple myeloma patients 
receiving three or more lines of therapy had a median time on treatment of approximately 2 
months29.  Therefore, i t is assumed that if multiple myeloma subjects who are carfilzomib -
refractory were retreat ed with carfilzomib plus low -dose dexamethasone , they would experience 
a median PFS of 2 months.  A 2 -month median PFS corresponds to a 4- month progression- free 
survival rate of 25% . In this patient population, if subjects treated with carfilzomib, ruxolitini b, 
and low -dose dexamethasone achieved a median PFS of 4 months, this would be considered a 
significant clinical benefit. A 4 -month median PFS corresponds to a 4- month progression- free 
survival rate of 50% . A Simon’s 2- stage design will be used to test the hypothesis that the 4-
month PFS rate is less than or equal to 25%.  Ten subjects  will be enrolled in the first stage, and 
if at least 3 of the 10 subjects  are alive and progress ion free at 4 months, an additional 20 
subjects  will be enrolled (a total of 30 subjects ).  If at least 11 of 30 subjects  are alive and 
progression free at 4 months, the null hypothesis will be rejected (based on binomial probabilities ).  Assuming a one -sided alpha = 0.10 significance level, this sample size will 
provide at least  90% power to reject the null hypothesis, assuming the true 4- month PFS rate is 
50%.    
13.2 Endpoint  Definitions  
For response and progression- related endpoints, the baseline disease assessment will be the one 
that occurred prior to the start of ruxolitinib therapy. 
13.2.1 Primary/ Phase I:  Dose Limiting Toxicity (DLT)  
DLT s will be determined for each subject  enrolled in Phase I as a binary variable indicating 
whether or not the subject  experienced a DLT ( as described in Section 4.2.1.3) during Cycle 1 of 
ruxolitinib treatment administration.  
13.2.2 Primary/ Phase II:  4- Month Progression -Free Survival  
4-month progression- free survival (PFS 4) will be determined for each subject  as a binary 
variable indicating whether or not the subject  is alive and progression free at 4 months. The 
timing of PFS 4 begins at the time subjects start treatment with ruxolitinib.  The criteria for 
progression are described in the IMWG Criteria (Appendix 18.3
).  
13.2.3 Progression -Free Survival  and Time to Progression  
PFS is defined as the duration of time from the initiation of study treatment with ruxolitinib  to 
first occurrence of either progressive disease or death.  D isease progres sion as  described by 
IMWG Criteria (Appendix 18.3 ).  The date of progressive disease is the date of the initial 
assessment that identified progressive disease.  If the subject dies  without documented disease 
progression, the date of progression will be the date of death.  For surviving subjects who do not 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
57 
 have documented disease progression, PFS will be censored at the date of last disease 
assessment.  For subjects who receive subse quent anti -cancer therapy prior to documented 
disease progression, PFS will be censored at the date of last disease assessment prior to the 
commencement of subsequent therapy.  Subjects who have an initial PFS event immediately 
following 2 or more consecut ive missed assessments will be censored at the date of the last 
assessment prior to those missed assessments.  For subjects  with only one missed assessment, the 
documented progressive disease status and assessment date will be used.  Time to progression 
(TTP) will be determined in a similar fashion as PFS, with the only difference being TTP will be 
censored at the death date for subjects who die without progressive disease.  
13.2.4 Overall Survival  
Overall survival is defined as the duration from initiation of rux olitinib treatment to the date of 
death from any cause.  Subjects who are alive or lost to follow -up at the time of the analysis will 
be censored at the l ast known date they were alive.  
13.2.5 Objective Response  
Objective response will be determined for each subj ect as a binary variable indicating whether or 
not the subject  achieved a best overall response of  PR or better as per the IMWG criteria after 
initiating treatment with ruxolitin ib.  
13.2.6 Clinical Benefit  
Clinical benefit will be determined for each subject  as a binary variable indicating whether or not 
the subject  achieved a best overall response of minimal response (MR)  or better as determined 
by the IMWG criteria  (MR adapted from EBMT)  after initiating treatment with ruxolitinib .  
13.2.7 Time to B est R esponse  
This will be calculated for all subjects  achieving a n sCR, CR, VGPR or PR and separately for 
subjects  achieving an MR and will be defined as the time from initiation of ruxolitinib treatment 
to the time of  best objective status assessment of sCR/CR/VGPR/PR or of MR.  
13.2.8 Disease control  
Disease control will be determined for each subject  as a binary variable indicating whether or not 
the subject  achieved an sCR, CR, VGPR, PR, MR or SD ≥ 8 weeks in duration after initiating 
treatment with ruxolitinib . 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
58 
 13.2.9 Duration of response  
Duration of response will be calculated for all subjects  achieving a n sCR, CR, VGPR or PR and 
separately for subjects  achieving an MR (defined per the EBMT criteria) and will be defined as 
the time from first objective status assessment of sCR/CR/VGPR/PR or of MR to the time of first 
documented disease progression or death.  The censoring mechanism for duration of response 
will be the same as that described for PFS.  
13.2.10 Safety Endpoints  
Safety endpoints will include  ruxolitinib  treatment administration, AEs, SAEs, deaths while on 
study therapy, vital signs, e jection fraction (%), and selected quantit ative laboratory 
determinations . Treatment administration will be determine d for each subject in terms of 
cumulative dose administration and dose intensity of ruxolitinib (adjusting for dose delays and 
reductions). Additionally, the relative dose intensity will be calculated for each subject in terms 
of the actual dose intensity as a percent of the in tended dose  intensity . 
Phase II:  Adverse Events of Special Interest (AESI)    
AESIs will be continuously monitored during the Phase II part of the study in subjects receiving 
ruxolitinib for the purposes of the pre -specified stopping rule described in Sec tion 13.4.3.  AESIs 
will be determined for each subject as a binary variable indicating whether or not the subject 
experienced a Grade 3/ 4/5 adverse event related to the ruxolitinib- containing regimen.  AESIs 
will consist of the following CTCAE terms: 
• Hear t failure  
• Pneumonia  
• Dyspnea  
• Peripheral edema  
• Hypertension  
13.3 Analysis Populations  
For the Phase I part of the study, the dose escalation and MTD evaluation will be conducted on 
the population who initiate Cycle 1, Day 1 treatment, and who meet the DLT evaluable criteria 
as described in Section 4.3.  For the Phase II part of the study, the PFS4 evaluable population 
will include all subjects who initiate treatment with ruxolitinib, have experienced a PFS event 
within 4 months from the start of ruxolitinib  treatment, or have at  least 4 months of follow up 
time from the start of ruxolitinib treatment.  The primary efficacy analysis will be conducted on 
the PFS4 ev aluable population.  Response -evaluable population will include all subjects (both 
Phase I and Phase II) who have baseline evaluation, measurable disease, and initiate study 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
59 
 treatment followed by at least one efficacy measurement . All response endpoints wi ll be 
conducted on the response -evaluable population.  
All other efficacy and ruxolitinib safety analyses will be conducted on the  population of subjects 
(both Phase I and Phase II) who initiate treatment with ruxolitinib . Additionally, an analysis will 
be conducted on safety data collected from Cycle 1 through the cycle prior to initiation of 
ruxolitinib treatment (for all Phase II subjects initiating Cycle 1  with carfilzomib plus 
dexamethasone ).  
13.4 Analysis Methods  
13.4.1 Timing of Analyses  
For the Phase I part of  the study, an evaluation of the data will take place after each subject  
completes Cycle 1.  For the Phase II part of the study, AES Is will be continuously evaluated in 
order to  assess the Bayesian stopping rules for toxicity described in Section 13.4.3.  Additionally, 
the stage 1 analysis will occur after the first 10 PFS evaluable subjects  enrolled have progressive 
disease, have died, or have at least 4 months of follow up time  from  ruxolitinib  treatment start.  
The stage 2 analysis will occur after 30 PFS evaluable subjects  have progressive disease, have 
died, or have at least 4 months  of follow up time .  For both Phase I and Phase II , a follow up 
analysis will occur when all e nrolled subjects  have progress ed, have died, have become lost to 
follow up or  withdrawn from the study, or have at least two years  of follow up time  after 
initiation of treatment with ruxolitinib .  A final analysis (for both Phase I and Phase II) will occu r 
when all subjects  have died , have become lost to follow up or withdrawn from the study, or have 
at least 3 years of follow up time after initiation of treatment with ruxolitinib.   
13.4.2 Efficacy An alyses  
13.4.2.1 Primary Analysis  (Phase II)  
The frequency and proportion of subjects  who are alive and progression free at 4 months will be 
calculated  with a corresponding 95% confidence interval using the Clopper -Pearson method.  A 
one-sided test for binomial proportions using the rejection regions  described in Section 13.1.2  
will be carried out, testing the null hypothesis that the PFS 4 rate is less than or equal to 25% .    
13.4.2.2 Secondary Analyses  
OS, PFS, time to progression, duration of response, and time to best response will be analyzed 
using Kaplan Meier techniques.  Medians, 25th, and 75th percentiles will be estimated.  Selected 
landmark rates will be estimated using the product limit function.  Objective response rate, disease control rate, and clinical benefit rate w ill be analyzed using frequencies and proportions.  
Ninety -five percent confidence intervals will be estimated using the Clopper -Pearson method.   
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
60 
 13.4.3 Safety Analyses  
Treatment administration will be summarized descriptively in terms of cumulative dose 
adminis tration and dose intensity of ruxolitinib (adjusting for dose delays and reductions). 
Additionally, the relative dose intensity will be calculated in terms of the actual dose intensity as 
percent of the intended dose intensity.  The maximum grade for each type of adverse event will 
be recorded for each subject  and treatment -emergent adverse events (TEAEs) will be identified .  
TEAEs are defined as follows:  
• An adverse event that occurs after treatment start that was not present at the time of 
treatment start; or  
• An adverse event that increases in severity after treatment start if the event was present at 
the time of treatment start.  
TEAEs will be summarized using f requencies and proportions , and these  will be reviewed to 
determine patterns.  Ad ditionally, the relationship of the adverse event(s) to the study treatment 
will be taken into consideration.  
Clinical laboratory tests (hematology, chemistry, coagulation panel , BNP ), vital signs, and 
ECHO/MUGA/cardiac MRI  (ejection fraction (%) ) will be summarized with descriptive 
statistics .  
Phase II Stopping Rule  
It is estimated that the composite rate of G rade 3 /4/5 AES Is (as defined in Section 13.2.10) in 
relapsed or refractory multiple myeloma patients treated with carfilzomib plus dexamethasone  is 
approximately 0.3030.  If it becomes evident that the G rade 3 /4/5 AESI rate convincingly exceeds 
0.30, the st udy will be halted. Enrollment will be su spended if the posterior probability of the 
Grade 3 /4/5 AESI rate exceeding 0.30 is 0.75 or higher.  T he prior distribution for this 
monitoring rule is beta ( 3,7).  This means that our prior assumption regarding the proportion of 
Grade 3 /4/5 AESI’s  is 0.30, and there is 90% probability that this proportion is between 0.098 
and 0.550.  The operating charact eristics of the stopping rule are given in the following table and 
are based on 5000 simulations.  
Operating Characteristics of the Stopping Rule  
Number of Subjects with an 
AESI  Number of Treated Subjects  Posterior Probability:  
Pr(AESI Rate>0.30|Data)  
3 5 0.781  
4 8 0.779  
5 11 0.761  
6 14 0.777  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
61 
 7 17 0.767  
8 20 0.768  
9 23 0.772  
10 26 0.770  
11 29 0.761  
 
13.4.4 Exploratory Analyses  
Logistic regression and Cox proportional hazards models will be used to assess the correlation 
between biomarkers and efficacy and toxicity outcomes.  Exploratory objectives include 
exploring the correlation of toxicities and disease response with:  
• Baseline serum cytokine profile  
• Baseline PBMC JAK inhibition  
• Baseline PBMC proteasome inhibition  
Genomic studi es will be performed on BM aspirate samples after sorting the CD138 positive and 
CD138 negative cells to understand mechanisms of carfilzomib sensitivity and resistance, along with modulation of the BM micro -environment. BM aspirate samples will be collected at:  
• Baseline (screening)  
• After Cycle # 1 (between Days 20 – 27)  of ruxolitinib 
• At time of disease relapse and/or progression after initiation of ruxolitinib  
13.5 Interim Analyses  
After 10 PFS evaluable subjects  have been enrolled to the Phase II part of the study, the study 
will be suspended for a planned interim analysis. The interim analysis w ill occur 4 months from 
the tenth  evaluable subject ’s enrollment (unless they have progressed or died first) and will 
determine if  at least  3 of 10 subjects  are alive and progression free at 4 months.  If the answer is  
yes, then t he study will re -open to accrual  and enroll  an additional 20 subjects  for a total of 30 
subjects . 
14 STUDY COMPLETION 
14.1 Completion  
The study will be considered complete when one or more of the following conditions is met:  
• All subjects have completed all study visits.  
• All subjects have discontinued from the study.  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
62 
 • The IRB, LCI DSMC, Sponsor -Investigator or funding companies disconti nue the study 
because of safety considerations.  
• The Sponsor -Investigator defines an administrative or clinical cut- off date.  
14.2 Termination  
The study will be terminated when one or more of the following conditions occur:  
• If risk -benefit ratio becomes unacceptable owing to, for example:  
o Safety findings from this study (e.g. SAEs)  
o Results of any interim analysis  
o Results of parallel clinical studies  
o Results of parallel animal studies (e.g.  toxicity, teratogenicity, carcinogenicity or 
reproduction toxicity).  
• If the study conduct (e.g. recruitment rate; drop- out rate; data quality; protocol 
compliance) does not suggest a proper completion of the trial within a reasonable time 
frame.  
The Spons or-Investigator has the right to close the trial at any site and at any time.  
For any of the above closures, the following applies:  
• Closures should occur only after consultation between involved parties.  
• All affected institutions must be informed as applic able according to local law.   
• In case of a partial study closure, ongoing subjects, including those in follow - up, must be 
taken care of in an ethical manner.  
15 ETHICAL AND LEGAL ISSUES  
15.1 Retention of Records  
Essential documentation (e.g. adverse events, reco rds of study drug receipt and dispensation), 
including all IRB correspondence, will be retained for at least 2 years after the investigation is completed.  Documentation will be readily available upon request . 
15.2 Ethical and Legal Conduct of the Study  
The procedures set out in this protocol, pertaining to the conduct, evaluation, and documentation 
of this study, are designed to ensure that the Investigator abide by Good Clinical Practice (GCP) 
guidelines and under the guiding principles detailed in the Decl aration of Helsinki.  The study 
will also be carried out in keeping with applicable local law(s) and regulation(s).  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
63 
 Documented approval from appropriate agencies (e.g. DSMC, IRB, FDA) will be obtained for 
all participating centers before start of the study , according to GCP, local laws, regulations and 
organizations.  When necessary, an extension, amendment or renewal of IRB approval must be 
obtained and forwarded to Amgen  and Incyte . 
Strict adherence to all specifications laid down in this protocol is requ ired for all aspects of study 
conduct; the Investigators may not modify or alter the procedures described in this protocol.   
Modifications to the study protocol will not be implemented by the Sponsor -Investigator without 
discussion and agreement by Amgen  and Incyte .  However, the Investigators may implement a 
deviation from, or a change of, the protocol to eliminate an immediate hazard(s) to the trial 
subjects without prior approval from applicable agencies.  As soon as possible, the implemented 
deviation or change, the reasons for it and if appropriate the proposed protocol amendment  
should be submitted to the appropriate agencies.  Any deviations from the protocol must be explained and documented by the Investigator. If a deviation occurs, the event shoul d be reported 
to the Sponsor -Investigator promptly. Any IRB reportable event that occurs must be reported to 
the IRB per IRB requirements. All planned (intentional) deviations must be submitted to the 
Sponsor -Investigator for approval prior to implementati on or planned occurrence. After Sponsor 
approval has been obtained, planned deviations must be submitted and approved by the IRB 
prior to the anticipated deviation occurring. Exceptions for eligibility criteria are not allowed.  
The Sponsor -Investigator  is responsible for the conduct of the clinical trial at the site s in 
accordance with Title 21 of the Code of Federal Regulations and/or the Declaration of Helsinki.  The Sponsor -Investigator  is responsible for personally overseeing the treatment of all study 
subject s.  The Sponsor -Investigator  must assure that all study site personnel, including sub-
investigator s and other study staff members, adhere to the study protocol and all applicable 
regulations and guidelines regarding clinical trials both during and a fter study completion. 
The Sponsor -Investigator  will be responsible for assuring that all the required data will be 
collected and properly documented.  
15.3 Confidentiality  
All records identifying the subject will be kept confidential and, to the extent permitted by the 
applicable laws and/or regulations, will not be made publicly available.  
16 PUBLICATION POLICY 
The Sponsor -Investigator must send a draft manuscript of the publication or abstract to Amgen  
and Incyte  prior to submission of the final version f or publication or congress presentation. All 
relevant aspects regarding data reporting and publication will be part of the contract between 
Amgen , Incyte  and the Sponsor -Investigator . 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
64 
 The Sponsor -Investigator will ensure that the information regarding the study be publicly 
available on the internet at www.clinicaltrials.gov .  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
65 
 17 REFERENCES  
1. Burger R , Bugdahn T, Staudinger M, et al . Preclinical activity of the JAK1/2 inhibitor 
ruxolitinib on malignant plasma cell gr owth and survival. J Clin Oncol 30, 2012 (suppl; abstr 
e18565)   
2. Orlowski RZ, Eswara JR, Lafond- Walker A, Grever MR, Orlowski M, Dang CV. Tumor 
growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome 
inhibitor. Cancer Res. 19 98;58:4342- 8. 
3. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The 
proteasome inhibitor PS -341 inhibits growth, induces apoptosis, and overcomes drug 
resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071- 6. 
4. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, et al. Molecular 
sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S 
A. 2002;99:14374- 9. 
5. Mitsiades N, Mitsiades CS, Poulaki V, Chauha n D, Richardson PG, Hideshima T, et al. 
Biologic sequelae of nuclear factor -kappaB blockade in multiple myeloma: therapeutic 
applications. Blood. 2002;99:4079- 86. 
6. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, et al. The proteasome  inhibitor PS -341 potentiates sensitivity of multiple myeloma cells to 
conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101:2377- 80. 
7. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, et al. Potent activity of carfilzomi b, a novel, irreversible inhibitor of the ubiquitin- proteasome pathway, against 
preclinical models of multiple myeloma. Blood. 2007;110:3281- 90. 
8. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, et al. Antitumor activity of PR-171, a novel irreversi ble inhibitor of the proteasome. Cancer Res. 2007;67:6383- 91. 
9. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, et al. Phase I trial of the proteasome inhibitor PS -341 in patients with refractory hematologic malignancies. 
J Clin Oncol . 2002;20:4420- 7. 
10. Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, et al. Phase 1 trial of 
the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with 
advanced hematologic maligna ncies. Blood. 2005;105:3058- 65. 
11. O'Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF, et al. A 
phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome 
inhibitor carfilzomib (PR -171) in patients with hematologic malignancies. Clin C ancer Res. 
2009;15:7085- 91. 
12. Alsina M, Trudel S, Furman RR, Rosen PJ, O'Connor OA, Comenzo RL, et al. A phase I 
single -agent study of twice -weekly consecutive -day dosing of the proteasome inhibitor 
carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin 
Cancer Res. 2012;18:4830- 40. 
13. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609- 17. 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
66 
 14. Richard son PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. 
Bortezomib or high- dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 
2005;352:2487- 98. 
15. Orlowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A, et al. Randomize d phase 
III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib 
alone in relapsed or refractory multiple myeloma: combination therapy improves time to 
progression. J Clin Oncol. 2007;25:3892- 901. 
16. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. 
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl 
J Med. 2008;359:906- 17. 
17. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, et al. A phase 2 study of 
single -agent carfilzomib (PX -171-003-A1) in patients with relapsed and refractory multiple 
myeloma. Blood. 2012;120:2817- 25. 
18. Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, et al. An open- label, 
single -arm, phase 2 (PX -171-004) study of single -agent carfilzomib in bortezomib -naive 
patients with relapsed and/or refractory multiple my eloma. Blood. 2012;119:5661- 70. 
19. Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, et al. An open-
label, single -arm, phase 2 study of single -agent carfilzomib in patients with relapsed and/or 
refractory multiple myeloma who have been previously treated with bortezomib. Br J 
Haematol. 2012;158:739- 48. 
20. Cenci S, Mezghrani A, Cascio P, Bianchi G, Cerruti F, Fra A, et al. Progressively impaired 
proteas omal capacity during terminal plasma cell differentiation. EMBO J. 2006;25:1104- 13. 
21. Bianchi G, Oliva L, Cascio P, Pengo N, Fontana F, Cerruti F, et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to 
proteasome inhibition. Blood. 2009;113:3040- 9. 
22. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516- 20. 
23. Brenner H, Gondos A, Pulte D. Expe cted long- term survival of patients diagnosed with 
multiple myeloma in 2006 -2010. Haematologica. 2009;94:270- 5. 
24. Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, et al. Long- term 
follow -up of autotransplantation trials for multiple myeloma: update of protocols conducted 
by the intergroupe francophone du myelome, southwest oncology group, and university of 
arkansas for medical sciences. J Clin Oncol. 2010;28:1209- 14. 
25. Usmani SZ, Crowley J, Hoering A, Mitchell A, Waheed S, Nair B, et al. Impr ovement in 
long- term outcomes with successive Total Therapy trials for multiple myeloma: are patients 
now being cured? Leukemia. 2013;27:226- 32. 
26. Anderson KC. The 39th David A. Karnofsky Lecture: bench -to-bedside translation of 
targeted therapies in multiple myeloma. J Clin Oncol. 2012;30:445- 52. 
27. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma 
relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
67 
 working group study. Leukemia. 2012 J an;26(1):149- 57.Navon A, Ciechanover A. The 26 S 
proteasome: from basic mechanisms to drug targeting. J Biol Chem. 2009;284:33713- 8. 
28. Kumar S, Paiva B, Anderson KC et al. International Myeloma Working Group consensus 
criteria for response and minimal residu al disease assessment in multiple myeloma. Lancet 
Oncol. 2016 Aug;17(8): e328- 46. 
29. Kumar SK, Dimopolous MA, Kastritis E  et al. Natural history of relapsed myeloma, 
refractory to  immunomodulatory drugs and proteasome inhibitors:  a multicenter IMWG 
study. Leukemia (2017) 31, 2443–2448. 
30. Dimopolous MA, Goldschmidt  H, Niesvizky  R et al. Carfilzomib or bortezomib in relapsed 
or refractory multiple  myeloma (ENDEAVOR): an interim overall survival analysis  of an 
open- label, randomised, phase 3 trial . Lancet Oncol 2017; 18: 1327–37.  
 
 
  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
68 
 18 APPENDICES  
18.1 ECOG Performance Scale 
 
Grade Description  
0 Normal activity, fully active, able to carry on all p re-disease 
performance without restriction.  
1 Symptoms, but fully ambulatory, restricted in physically 
strenuous but ambulatory and able to carry out work of a light or 
sedentary nature (e.g. light housework, office work). 
2 Ambulatory and capable of all self -care but unable to carry out 
any work activities.  Up and about more than 50% of waking 
hours. 
3 Capable of only limited self -care, confined to bed or chair more 
than 50% of waking hours. 
4 Completely disabled.  Cannot carry on any self -care.  Totally 
confined to bed or chair.  
5 Dead  
 
 
               
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
69 
 18.2 NCI CTCAE VERSION 4.03  
 
 
Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute 
(NCI) v4.03  
 
Publish Date: (v4.03: June 14, 2010)  
 
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010- 06-14_QuickReference_8.5x11.pdf  
 
 
18.3 Response Criteria for Multiple Myeloma   
IMWG Response Criteria *  
IMWG MRD Criteria (Requires a complete response as defined below)  
Sustained MRD -
negative  MRD negativity in the marrow (NGF or NGS, or both) and by imaging as defined below, 
confirmed minimum of 1 year apart. Subsequent evaluations can be used to further specify 
the duration of negativity (eg, MRD -negative at 5 years) † 
Flow MRD -negative  Absence of phenotypically aberrant clonal plasma cells by NGF‡ on bone marrow aspirates 
using the EuroFlow standard operation procedure for MRD detection in multiple myeloma  
(or validated equivalent method) with a minimum sensitivity of 1 in 10⁵  nucleated cells or 
higher  
Sequencing MRD -
negative  Absence of clonal plasma cells by NGS on bone marrow aspirate in which presence of a 
clone is defined as less than two identical sequencing reads obtained after DNA sequencing 
of bone marrow aspirates using the Lymp hoSIGHT platform (or validated equivalent 
method) with a minimum sensitivity of 1 in 10 ⁵ nucleated cells § or higher  
Imaging -positive 
MRD -negative  MRD negativity as defined by NGF or NGS plus disappearance of every area of increased 
tracer uptake found at baseline or a preceding PET/CT or decrease to less mediastinal blood 
pool SUV or decrease to less than that of surrounding normal tissue ¶ 
Standard IMWG Response Criteria ||; NOTE: see [28] for additional details  
Stringent Complete 
Response  
(sCR)  • Complete response as defined below plus normal FLC ratio** and absence of clonal 
cells in bone marrow biopsy by immunohistochemistry (κ/λ ratio ≤4:1 or ≥1:2 for  
             κ and λ patients, respectively, after counting ≥100 plasma cells)††  
Complete Response  
(CR)  • Negative immunofi xation on the serum and urine and disappearance of any soft 
tissue plasmacytomas and <5% plasma cells in bone marrow aspirates. In patients 
with only FLC disease, a normal FLC ratio of 0.26 –1.65 is required.  
Very G ood Partial 
Response  • Serum and urine M -protein detectab le by immunofi xation but not on electrophoresis 
or ≥90% reduction in serum M -protein plus urine M -protein level <100 mg  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
70 
 (VGPR)  per 24 h  
Partial Response  
(PR)  • ≥50% reduction of serum M -protein plus reduction in 24 h urinary M -protein by 
≥90% or to <200 mg per 24 h;  
• If the serum and urine M -protein are unmeasurab le, a ≥50% decrease in the 
difference between involved and uninvolved FLC levels is required in place of the  
M-protein criteria;  
• If serum and urine M -protein are unmeasurable, and serum -free light assay is also 
unmeasurable, ≥50% reduction in plasma cells is required in place of M -protein,  
provided baseline bone marrow plasma -cell percentage was ≥30%. In addition to 
these criteria, if present at baseline, a ≥50% reduction in the size (SPD)§§ of soft  
tissue plasmacytomas is also required  
Minimal Response 
(MR)  • ≥25% but ≤49% reduction of serum M -protein and reduction in 24 -h urine M -protein 
by 50–89%. In addition to the above listed criteria, if present at baseline, a  ≥50% 
reduction in the size (SPD)§§ of soft tissue plasmacytomas is also required . 
Stable Disease (SD)  • Not recommended for use as an indicator of response; stability of disease is best 
described by providing the time -to-progression estimates  
• Not meeting criteria for CR, VGPR, PR , MR  or progressive disease  
Progressive disease  
(PD) ¶¶, |||| Increase of  > 25% from lowest response value in any one  or more  of the following:  
• Serum M -protei n (absolute increase must be ≥0.5 g/dL);  
• Serum M -protein increase ≥1 g/dL, if the lowest M component was ≥5 g/dL;  
• Urine M -protein (absolute increase must be ≥200 mg/24 h);  
• In patients without measurable serum and urine M -protein le vels, the diff erence 
between involved and uninvolved FLC levels (absolute increase must be >10 
mg/dL);  
• In patients without measurable serum and urine M -protein levels and without 
measurable involved FLC levels, bone marrow plasma -cell percentage irrespective of  
baseline status (absolute increase must be ≥10%);  
• Appearance of a new lesion(s), ≥50% increase from nadir in SPD§§ of >1 lesion, or 
≥50% increase in the longest diameter of a previous lesion >1 cm in short axis;  
• ≥50% increase in  circulating plasma cells (minimum of 200 cells per μL) if this is the 
only measure of disease  
r 
Clinical Relapse  Clinical relapse requires one or more of the following criteria:  
• Direct indicators of increasing disease and/or end organ dysfunction (CRAB 
features) related to the underlying clonal plasma -cell proliferative disorder. It is not 
used in calculation of TTP or PFS but is listed as something that can be reported 
optionally or for use in clinical practice;  
• Development of new soft tissue plasmacytomas or bone lesions (osteoporotic 
fractures do not constitute progression);  
• Definite increase in the size of existing plasmacytomas or bone lesions. A definite 
increase is defined a s a 50% (and ≥1 cm) increase as measured serially by the 
SPD§§of the measurable lesion;  
• Hypercalcaemia (>11 mg/dL);  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
71 
 • Decrease in haemoglobin of ≥2 g/dL not related to therapy or other non -myeloma -
related conditions;  
• Rise in serum creatinine by 2 mg/dL or mo re from the start of the therapy and 
attributable to myeloma;  
• Hyperviscosity related to serum paraprotein  
For MRD assessment, the first bone marrow aspirate should be sent to MRD (not for morphology) and this 
sample should be taken in one draw with a volume of minimally 2 mL (to obtain sufficient cells), but 
maximally 4 –5 mL to avoid haemodilution. IMWG=International Myeloma Working Group. MRD=minimal 
residual disease. NGF=next -generation flow. NGS=next -generation sequencing. FLC=freelight chain. M -
protein=myeloma protein. SPD=sum of the products of the maximal perpendicular diameters of measured 
lesions. CRAB features=calcium elevation, renal failure, anaemia, lytic bone lesions. FCM=flow cytometry. 
SUV max=maximum standardised uptake value. MFC=multiparame ter flow cytometry. 18F-FDG PET=18F-
fluorodeoxyglucose PET. ASCT=autologous stem cell transplantation.  
* All response categories require two consecutive assessments made any time before starting any new 
therapy; for MRD there is no need for two consecutive assessments, but information on MRD after each 
treatment stage is recommended (e.g., after induction, high- dose therapy/ASCT, consolidation, 
maintenance). MRD tests should be initiated only at the time of suspected complete response. All categories of response and MRD require no known evidence of progressive or new bone lesions if radiographic studies were performed. However, radiographic studies are not required to satisfy these response requirements 
except for the requirement of FDG PET if imaging MRD -negative status is reported. †Sustained MRD 
negativity when reported should also annotate the method used (e .g., sustained flow MRD -negative, 
sustained sequencing MRD -negative).  
‡ Bone marrow MFC should follow NGF guidelines.
30 The reference NGF method is an eight -colour two-
tube approach, which has been extensively validated. The two- tube approach improves reliability, 
consistency, and sensitivity because of the acquisition of a greater number of cells. The eight -colour 
technology is widely available globally and the NGF method has already been adopted in many flow 
laboratories worldwide. The complete eight -colour method is most efficient using a lyophilised mixture of 
antibodies which reduces errors, time, and costs. 5 million cells should be assessed. The FCM method employed should have a sensitivity of detection of at least 1 in 10⁵ plasma cells.  
§ DNA sequencing assay on bone marrow aspirate should use a validated assay such as LymphoSIGHT 
(Sequenta).  
¶ Criteria used by Zamagni and coll eagues,
85 and expert panel (IMPetUs; Italian Myeloma criteria for PET 
Use).81,97 Baseline positive lesions were identified by presence of focal areas of increased uptake within 
bones, with or without any underlying lesion identified by CT and present on at  least two consecutive slices. 
Alternatively, an SUV max=2.5 within osteolytic CT areas >1 cm in size, or SUV max=1.5 within osteolytic CT 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
72 
 areas ≤1 cm in size were considered positive. Imaging should be performed once MRD negativity is 
determined by MFC or N GS.  
|| Derived from international uniform response criteria for multiple myeloma.11 Minor response definition 
and c larifications derived from Raj K umar and colleagues.14 When the only method to measure disease is by 
serum FLC levels: complete response can  be defined as a normal FLC ratio of 0.26 to 1.65 in addition to the 
complete response criteria listed previously. Very good partial response in such patients requires a ≥90% 
decrease in the difference between involved and uninvolved FLC levels. All response categories require two 
consecutive assessments made at any time before the institution of any new therapy; all categories also 
require no known evidence of progressive or new bone lesions or extramedullary plasmacytomas if radiographic studies were perf ormed. Radiographic studies are not required to satisfy these response 
requirements. Bone marrow assessments do not need to be confirmed. Each category, except for stable 
disease, will be considered unconfirmed until the confirmatory test is performed. The  date of the initial test 
is considered as the date of response for evaluation of time dependent outcomes such as duration of 
response.  
** All recommendations regarding clinical uses relating to serum FLC levels or FLC ratio are based on 
results obtained with the validated Freelite test (Binding Site, Birmingham, UK).  
†† Presence/absence of clonal cells on immunohistochemistry is based upon the κ/λ/L ratio. An abnormal 
κ/λ ratio by immunohistochemistry requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting presence of an abnormal clone is κ/λ of >4:1 or <1:2.  
‡‡ Special attention should be given to the emergence of a different monoclonal protein following treatment, 
especially in the setting of patients having achieved a convent ional complete response, often related to 
oligoclonal reconstitution of the immune system. These bands typically disappear over time and in some studies have been associated with a better outcome. Also, appearance of monoclonal IgG κ in patients receiving monoclonal antibodies should be differentiated from the therapeutic antibody.  
§§ Plasmacytoma measurements should be taken from the CT portion of the PET/CT, or MRI scans, or 
dedicated CT scans where applicable. For patients with only skin involvement, skin lesions should be measured with a ruler. Measurement of tumour size will be determined by the SPD. 
¶¶ Positive immunofixation alone in a patient previously classified as achieving a complete response will not 
be considered progression. For purposes of c alculating time to progression and progression- free survival, 
patients who have achieved a complete response and are MRD -negative should be evaluated using criteria 
listed for progressive disease. Criteria for relapse from a complete response or relapse fr om MRD should be 
used only when calculating disease -free survival.  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
73 
  
  |||| In the case where a value is felt to be a spurious result per physician discretion (eg, a possible laboratory 
error), that value will not be considered when determining the lowest val ue. 
 
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
74 
  
18.4 Estimated Creatinine Clearance rate (eCCr) using Cockcroft -Gault Formula  
 
 
 
 
 
   

Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
75 
 18.5 Table of Events  
 
 
Evaluation   
Days -21 
to -1 
(Baseline)  Phase I and Phase II  
All Cyclest (cycle = 28 days)  
Subjects in Phase II/Run -In period only: Please note cycle numbers will start 
over with ‘Cycle 1 ’ after initiation of ruxolitinib  End of 
Treatmentq Follow -
upr 
Day 1  Day 2x Day 8x Day 9x Day 15x Day 16x Day 22x   
Informed consent a X          
Inclusion/exclusion  X          
Medical and disease history b X          
Physical examination/BSA c X Xs       X  
Vital signsd  X X X X X X X X X  
ECOG performance status  X Xs       X  
Pregnancy test e X        X  
Electrocardiogram  X          
Echocardiogram , MUGA , or 
cardiac MRIf X X  
(prior to 
every 2 
cycle s)                X.  
Hematology g X X s X X X X X X X  
Coagulation h X X s         
Blood chemistries i X X s  X  X  X X  
BNPw  Xs         
Viral hepatitis panelv X          
HBV DNA testingy X          
Bone marrow j X (X)       Xl (X)r 
Correlative studies  
(Blood and bone marrow)l X   Xl 
 (Cycle 1  of 
ruxolitinib  
only;  
Blood only)     Xl  
(Cycle 1 of 
ruxolitinib 
only day 20 
-27) Xl  
Response assessments 
(SPEP/UPEP, IFE, SFLC) k,u X X        X (X)r 
Serum β2 -microglobulin  X          
Assessment of plasmacytomam X (X)       (X) (X)r 
Bone skeletal surveyn X (X)       (X)  
Carfilzomib administrationo  X X X X X X    
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
76 
 Ruxolitinib administrationo  Twice Daily days 1 – 28  
Phase I all subjects. Phase II: Subjects with < PR following Phase II/Run -In period, subjects ≥ PR 
following Phase II/Run -In period  who then subsequently progress , and subjects who proceed 
directly to Phase II/Ruxolitinib     
Dexamethasone 
administrationo  X  X  X     
Concomitant medications p X  X  
Adverse event monitoring    X  
Follow -up    Xr 
 
(X) only if clinically indicated  
a) All subjects  must sign an IRB -approved informed consent document prior to enrollment and prior to any study related procedures.   
b) Medical History including demographics, prior and current medical illness and conditions  (including baseline symptoms and toxicities) , prior surgical 
procedures. Disease histo ry includes date of initial diagnosis, stage and extent of the disease, Prior anticancer therapy (types and response), surger y and/or 
radiation including documentation of sensitive or refractory status, (refractory defined as documented disease progression during or within 60 days of 
completing the last anti- myeloma  regimen ), and d ocumentation of Proteasome Inhibitor refractory disease status.  
c) A complete physical exam, including height (screening only) and weight, neurologic assessment and assessment for extramedullary myeloma will be 
conducted at screening, day one of each cycle and End of Treatment visit. A symptom directed physical examination will be conducted as needed during 
a cycle.  Plasmacytomas that can be followed by physical exam are to be evaluated on day one of each cycle.  Weight to be measured on day one of each cycle with calculation of BSA ( Subjects  with a BSA > 2.2 m
2 should receive a c arfilzomib dose based on a 2.2 m2 BSA).  Dose adjustments do not need 
to be made for weight changes of less  than or equal to 20% from baseline weight.  Baseline symptoms and residual toxicity from previous therapy assessed 
within 14 days prior to initiation of therapy.  
d) Vital signs including blood pressure, pulse, respiration rate, temperature.  To be performed prior to each c arfilzomib infusion and as clinically indicated.  
e) For females of childbearing potential, a negative serum pregnancy test must be documented within 7 days and a negative urine pregnancy test within  3 
days of C1D1.  A female of childbearing potential (FCBP) is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral o ophorectomy; 
or 2) has not been naturally postmenopausal for at lea st 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).  
f) Echocardiogram , MUGA,  or cardiac MRI  to be performed at baseline , every 2 cycles  (within 5 days  of Day 1) , and end of therapy to calculate LVEF.  
Subjects  who develop signs/symptoms of congestive heart failure at any point during the study are required to have an evaluation of LV EF measurements 
by ECHO , MUGA,  or cardiac MRI , preferably by the same method used at screening . If echo cardiogram , MUGA,  or cardiac MRI  is done within 2 months 
from End of Treatment  visit, it does not need to be repeated.  
g) Hematology: hemoglobin, WBC with differential, and platelet count.  
h) Coagulation: prothrombin time (PT), international normalized ratio (INR).  
i) Blood chemistry:  sodium , chloride, potassium, magnesium, phosphate, uric acid, BUN, glucose (fasting at baseline), ALT/AST (SGPT/SGOT), alkaline 
phosphatase, total protein, total bilirubin, albumin, serum creatinine, and estimated creatinine clearance by Cockc roft-Gault Equation s (Appendix 18.4 ) 
calcium and lactate dehydrogenase (LDH). Creatinine clearance required on days of the cycle other than Day 1 may be calculated using the Day 1 weight of the current cycle.  
j) Bone marrow aspirate to be collected at screening for % plasma cells, morphology, standard karyotype, cytogenetics by FISH and biomarkers . Repeat for 
% plasma cells at the time of CR and/ or progression. Screening timepoint only: If bone marrow previously collected for pathology evaluation as previously 
described within 21 days prior to initiation of study therapy, the pathology evaluation does not need to be repeated as part of the s creening 
assessments.   However, a bone marrow aspirate must be performed for correlative studies (see Footnote L for information on correlative studies) .  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
77 
 k) Serum or urine protein electrophoresis (SPEP, UPEP), serum and urine immunofixation (IFE) and serum free light chain (SFLC) assay.  To be conducted 
prior to each cycle  (within 7 days of Day 1) until documentation of initial disease progression . For cycles delayed ≤ 7 days, repeat evaluations are not 
required.  If the start of a new cycle is delayed > 7 days a repeat disease evaluation must be performed prior to the subsequent cycle. Phase II/Run -In 
subjects who cross over to Phase II/Ruxolitin ib only: Disease responses will be calculated from disease evaluation performed just prior to initiating 
ruxolitinib (a new baseline will be established).  
l) Blood and bone marrow samples will be collected for correlatives prior to study treatment initiation (collection is recommended after eligibility is 
established; baseline samples  may be collected  during screening or  pre-treatment on C1D1) ; Cycle  1 of ruxolitinib , between Day 20 -27; and at disease 
relapse or progression after ruxolitin ib has been initiated . Blood only will be collected on C1D8 of ruxolitinib. These correlative labs include serum 
cytokines panel, peripheral blood mononuclear cells (PBMC) for proteasome inhibition, and PBMCs for JAK inhibition.  Approximately 28 mLs of blood 
will be collected (please refer to the Correlative Guidelines for the type of tube s required) and will be sent to the LCI HOT lab.  A minimum of  12 mL  
(first or second pull permitted) of bone marrow aspirate will be collected  and sent to the LCI HO T lab. Note: ruxolitinib must have been initiated to collect 
correlative  samples  post-baseline (do not collect p ost-baseline correlative samples on subjects receiving study treatment in Phase II/Run- In period ). Every 
effort should be made to collect post -baseline correlative samples prior to carfilzomib and dexamethasone administration; after the morning ruxolitinib 
dose and before the afternoon dose of ruxolitinib.  Correlatives collected during screening do not need to be re -collected in the event that the screening 
period extends beyond 21 days.  
m) Known or suspected plasmacytomas are to be assessed at baseline, as clinically indicated and to confirm response and/ or progression. FDG -PET is not 
required but suggested. The same method of evaluation should be used throughout the study (CT/MRI/PET ). Phase II/Run -In subjects who cross over to 
Phase II/Ruxolitinb only: For s ubjects with plasmacytomas  present at screening, imaging using the same modality utilized at screening will be repeated 
prior to initiating  ruxolitinib  (a new baseline will be established).  
n) Skeletal survey includes plain X -rays of (including skull, all long bones, pelvis  and chest) required if previous survey >12 weeks from study entry and at 
any time when clinically indicated.  
o) See section 5 for complete details on study drug administration, dose modifications and start of a new cycle of therapy.  
p) Concomitant medications and procedures: - all procedures and medications within 14 days prior to first dose until 30 days after the last dose.  
q) End of Treatment visit should be completed within 30 days of last dose of study drug with evaluation of safety at 30 days or prior to ini tiation of subsequent 
therapy (whichever comes first)  
r) Subjects  who received ruxolitinib on study and discontinue therapy for reasons other than disease progression should continue to have disease assessments 
per standard of care done until progression or s tart of subsequent therapy.  At such time, follow -up for overall survival status will take place every three 
months +/ - 7 days until death, lost to follow -up, or until the criteria defined for the final analysis (Section 13.4.1) are reached. Follow -up beyond the safety 
follow -up period is only required for subjects who received ruxolitinib.  Follow -up may be completed by phone contact. Death information from public 
sources, e.g. death registry, obituary listing, etc. can also be used when it is available and verifiable  
s) C1D1  procedures do not need to be repeated if the screening procedure  occurred within 5 days  (this applies to C1D1 following screening; does not apply 
to C1D1 of Phase II/Ruxolitinib in subjects who cross over from Phase II/Run- In); Day 1 proce dures for subsequent cycles do not need to be repeated if 
done within 3 days of Day 1.  
t) +/- 3 day window permitted for holidays/administrative reasons  
u) Phase II /Run -In period only: Beginning with Cycle 1 , disease evaluation results to assess response should be available for investigator review prior to 
dosing on Day 1 of each cycle (within 7 days of Day 1)  until initiation of ruxolitinib (after ruxolitinib has been initiated, disease evaluation assessments 
will continue to be collected prior to dosing on Day 1, but results will not be required to be available prior to Day 1 dosing).  Cycle numbers start over 
with the initiation of ruxolitinib and a new disease response baseline will be established . 
v) Viral hepatitis panel including HBsAg, HB core antibody, HB surface antibody, Hep C antibody and HIV at baseline only.  
w) BNP to be done Day 1 (+/- 3 days)  of every cycle.  
Protocol Number:  LCI -HEM -MYE -CRD -004 
     Version 6:  September  27, 2022 
 
78 
 x) A +/- 1 day window is allowed for study treatment on Days 2, 8, 9, 15, and 16 and procedures on Day 22, unless otherwise noted. All procedures required 
for Days 2, 8, 9, 15, and 16 should be performed within 1 day of study treatment, unless otherwise noted.  
y) For subjects with serologic evidence of resolved HBV infection (i.e. positive anti- HBs or positive anti -HBc) at Screening. HBV DNA testing by PCR 
must be performed locally. Subjects with serologic findings suggestive of HBV vaccination (Anti -HBs positivity as the only serologic marker) and a 
known history of prior HBV vaccination do not need to be tested for HBV DNA by PCR . 
 
 
 